General References



Baba T, Touchi A, Ito K et al. Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism. Drug Metab Pharmacokinet 2002; 17:522-31.

Babalola CP, Adejumo O, Ung D et al. Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. J Clin Pharm Ther 2010; 35:471-7.

Babalola CP, Kolade YT, Olaniyi AA, Adedapo A, Scriba GK. Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers. J Clin Pharm Ther 2009; 34:677-82.

Babaoglu MO, Ocal T, Bayar B, Kayaalp SO, Bozkurt A. Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population. Eur J Clin Pharmacol 2004; 59:875-7.

Babaoglu MO, Yasar U, Sandberg M et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004; 60:337-42.

Babbar S, Chanda S, Bley K. Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 2010; 40:807-16.

Babenko AP, Polak M, Cavé H et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456-66.

Babić Z, Kucisec-Tepes N, Troskot R, Dorosulić Z, Svoboda-Beusan I. The importance of P-glycoprotein multidrug transporter activity measurement in patients with Helicobacter pylori infection. Coll Antropol 2009; 33:1145-50.

Babic Z, Svoboda-Beusan I, Kucisec-Tepes N, Dekaris D, Troskot R. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. World J Gastroenterol 2005; 11:2720-5.

Babron MC, Nilsson S, Adamovic S et al. Meta and pooled analysis of European coeliac disease data. Eur J Hum Genet 2003; 11:828-34.

Babu E, Takeda M, Narikawa S et al. Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol 2002; 88:69-76.

Baccarelli A, Calista D, Minghetti P et al. XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk. Br J Cancer 2004; 90:497-502.

Bäck M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 2009; 15:3116-32.

Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 2006; 62:451-61.

Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68:122-9.

Backman JT, Mäenpää J, Belle DJ, Wrighton SA, Kivistö KT, Neuvonen PJ. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clin Pharmacol Ther 2000; 67:382-90.

Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59:7-13.

Backman JT, Wang JS, Wen X, Kivistö KT, Neuvonen PJ. Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. Clin Pharmacol Ther 1999; 66:401-7.

Bacher I, Wu B, Shytle DR, George TP. Mecamylamine – a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. Expert Opin Pharmacother 2009; 10:2709-21.

Bachleda P, Vrzal R, Dvorák Z. Activation of MAPKs influences the expression of drug-metabolizing enzymes in primary human hepatocytes. Gen Physiol Biophys 2009; 28:316-20.

Bachleda P, Vrzal R, Pivnicka J, Cvek B, Dvorak Z. Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes. Toxicol Lett 2009; 191:74-8.

Bachmakov I, Glaeser H, Fromm MF, König J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 2008; 57:1463-9.

Bachman ES, Dhillon H, Zhang CY et al. Beta-AR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002; 297:843-5.

Bachmann K, He Y, Sarver JG, Peng N. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica 2003; 33:265-76.

Bachmann K, Jauregui L, Chandra R, Thakker K. Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. Pharmacol Res 2003; 47:549-54.

Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur J Pharmacol 2011; 659:124-9.

Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 2011; 32:233-44.

Bachus R, Bickel U, Thomsen T, Roots I, Kewitz H. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9:661-8.

Badagnani I, Castro RA, Taylor TR et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 2006; 318:521-9.

Badal S, Williams SA, Huang G et al. Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri. Fitoterapia 2011; 82:230-6.

Badaracco MA. Keeping our depressed patients in the right treatment long enough for them to get better: some hopeful findings. Am J Psychiatry 2007; 164:1136-9.

Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 2001; 50:1001-3.

Bader A, Hansen T, Kirchner G, Allmeling C, Haverich A, Borlak JT. Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. Br J Pharmacol 2000; 129:331-42.

Bader MI, Wober J, Kretzschmar G, Zierau O, Vollmer G. Comparative assessment of estrogenic responses with relevance to the metabolic syndrome and to menopausal symptoms in wild-type and aromatase-knockout mice. J Steroid Biochem Mol Biol 2011. doi:10. 1016/j. jsbmb. 2011. 05. 004.

Badruddin A, Gorelick PB. Antiplatelet therapy for prevention of recurrent stroke. Curr Treat Options Neurol 2009; 11:452-9.

Badyal DK, Dadhich AP. Cytochrome P450 and drug interactions. Indian J of Pharmacol 2001; 33:248-59.

Bae JW, Choi CI, Jang CG, Lee SY. Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 2011; 71:550-5.

Bae JW, Choi CI, Kim MJ et al. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 2011; 32:1303-8.

Bae JW, Choi CI, Lee JH, Jang CG, Chung MW, Lee SY. Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. Eur J Clin Pharmacol 2011; 67:39-45.

Bae JW, Jang CG, Lee SY. Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J Clin Pharmacol 2011. doi:10. 1177/0091270010388651.

Bae JW, Kim JH, Choi CI et al. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch Pharm Res 2009; 32:269-73.

Bae SH, Bae SK, Lee MG. Effect of hepatic CYP inhibitors on the metabolism of sildenafil and formation of its metabolite, N-desmethylsildenafil, in rats in vitro and in vivo. J Pharm Pharmacol 2009; 61:1637-42.

Bae SH, Sung SH, Cho EJ et al. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology 2011; 53:945-53.

Bae SK, Cao S, Seo KA et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos 2008; 36:1679-88.

Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001; 15:991-8.

Baede-van Dijk PA, van Galen E, Lekkerkerker JF. Drug interactions of Hypericum perforatum (St. John’s wort) are potentially hazardous. Ned Tijdschr Geneeskd 2000; 144:811-2.

Baek MS, Kim JY, Myung SW, Yim YH, Jeong JH, Kim DH. Metabolism of dimethyl-4,4’-dimethoxy-5,6,5’,6’-dimethylene dioxybiphenyl-2,2’-dicarboxylate (DDB) by human liver microsomes: characterization of metabolic pathways and of cytochrome P450 isoforms involved. Drug Metab Dispos 2001; 29:381-8.

Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappa-B and beta-amyloid precursor protein. Cell 2002; 110:55-67.

Baer BR, Rettie AE, Henne KR. Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chem Res Toxicol 2005; 18:855-64.

Baer BR, Rettie AE. CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug Metab Rev 2006; 38:451-76.

Baer BR, Wienkers LC, Rock DA. Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 2007; 20:954-64.

Bafica A, Scanga CA, Serhan C et al. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 2005; 115:1601-6.

Baghdasaryan A, Claudel T, Kosters A et al. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010; 59:521-30.

Bagnoli F, de Oliveira VM, da Silva MA, Taromaru GC, Rinaldi JF, Aoki T. The interaction between aromatase, metalloproteinase 2,9 and CD44 in breast cancer. Rev Assoc Med Bras 2010; 56:472-7.

Bagriantsev S, Liebman S. Modulation of Aβ42 low-n oligomerization using a novel yeast reporter system. BMC Biol 2006; 4:32.

Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010; 46:308-16.

Bah J, Quach H, Ebstein RP et al. Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. Neuroreport 2004; 15:1987-91.

Bahadur N, Leathart JB, Mutch E et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64:1579-89.

Bahar AY, Taylor PJ, Andrews L et al. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U. S. population data. Cancer 2001; 92:440-5.

Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Bouskela E. Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome. Arq Bras Cardiol 2006; 86:366-73.

Bahn A, Prawitt D, Buttler D et al. Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene. Biochem Biophys Res Commun 2000; 275:623-30.

Bahn S, Mimmack M, Ryan M et al. Neuronal target of the neuron-restrictive silencer factor in neuropheres derived from fetuses with Down’s syndrome: a gene expression study. Lancet 2002; 359:310-5.

Bahrami F, Yousefpour M, Mehrani H et al. Type of cell death and the role of acetylcholinesterase activity in neurotoxicity induced by paraoxon in cultured rat hippocampal neurons. Acta Biol Hung 2009; 60:1-13.

Bai C, Matsui E, Ohnishi H et al. A novel polymorphism, E254K, in the 5-lipoxygenase gene associated with bronchial asthma. Int J Mol Med 2008; 21:139-44.

Bai N, Kido T, Suzuki H et al. Changes in atherosclerotic plaques induced by inhalation of diesel exhaust. Atherosclerosis 2011; 216:299-306.

Bai S, Stepkowski SM, Kahan BD, Brunner LJ. Metabolic interaction between cyclosporine and sirolimus. Transplantation 2004; 77:1507-12.

Bai Y, Yu Y, Yu B et al. Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet 2009; 10:125.

Bai YM, Chen TT, Liou YJ, Hong CJ, Tsai SJ. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res 2011; 125:179-86.

Baier LJ, Sacchettini JC, Knowler WC et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995; 95:1281-7.

Baigent A, Lashen H. Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. Fertil Steril 2011; 95:2429.

Bailey DG, Bend JR, Arnold JM, Tran LT, Spence JD. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996; 60:25-33.

Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 2003; 73:529-37.

Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 2000; 68:468-77.

Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007; 81:495-502.

Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4:281-97.

Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46:101-10.

Bailey KM, Romaine SP, Jackson BM et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet 2010; 3:276-85.

Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998; 58:5038-41.

Bains OS, Karkling MJ, Grigliatti TA, Reid RE, Riggs KW. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos 2009; 37:1107-14.

Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39:1336-45.

Baird PN, Guida E, Chu DT, Vu HT, Guymer RH. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004; 45:1311-5.

Baitsch D, Bock HH, Engel T et al. Apolipoprotein e induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol 2011; 31:1160-8.

Bajaj G, Rodriguez-Proteau R, Venkataraman A, Fan Y, Kioussi C, Ishmael JE. MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun 2010; 398:7-12.

Bajgai SP, Prachyawarakorn V, Mahidol C, Ruchirawat S, Kittakoop P. Hybrid flavan-chalcones, aromatase and lipoxygenase inhibitors, from Desmos cochinchinensis. Phytochemistry 2011; 72:2062-7.

Bajgar J, Fusek J, Kassa J, Jun D, Kuca K, Hajek P. An attempt to assess functionally minimal acetylcholinesterase activity necessary for survival of rats intoxicated with nerve agents. Chem Biol Interact 2008; 175:281-5.

Bajgar J, Fusek J, Kuca K, Bartosova L, Jun D. Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. Mini Rev Med Chem 2007; 7:461-6.

Bajgar J, Hajek P, Slizova D et al. Changes of acetylcholinesterase activity in different rat brain areas following intoxication with nerve agents: biochemical and histochemical study. Chem Biol Interact 2007; 165:14-21.

Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24:1401-3.

Bajrami B, Zhao L, Schenkman JB, Rusling JF. Rapid LC-MS drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format. Anal Chem 2009; 81:9921-9.

Bajt ML, Ramachandran A, Yan HM et al. Apoptosis-inducing factor modulates mitochondrial oxidant stress in acetaminophen hepatotoxicity. Toxicol Sci 2011; 122:598-605.

Bak S, Tsiropoulos I, Kjaersgaard JO et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33:1465-73.

Bakare-Odunola MT, Enemali I, Garba M, Obodozie OO, Mustapha KB. The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects. Eur J Drug Metab Pharmacokinet 2008; 33:165-71.

Baker AD, Malur A, Barna BP, Kavuru MS, Malur AG, Thomassen MJ. PPARgamma regulates the expression of cholesterol metabolism genes in alveolar macrophages. Biochem Biophys Res Commun 2010; 393:682-7.

Baker DE. Loperamide: a pharmacological review. Rev Gastroenterol Disord 2007; 7 Suppl 3:11-8.

Baker EK, El-Osta A. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing. Methods Mol Biol 2010; 596:183-98.

Baker JR, Best AM, Pade PA, McCance-Katz EF. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother 2006; 40:392-6.

Baker JR, Edwards RJ, Lasker JM, Moore MR, Satarug S. Renal and hepatic accumulation of cadmium and lead in the expression of CYP4F2 and CYP2E1. Toxicol Lett 2005; 159:182-91.

Baker JR, Satarug S, Reilly PE et al. Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples. Biochem Pharmacol 2001; 62:713-21.

Baker M, Litvan I, Houlden H et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999; 8:711-5.

Baker M, Rahman T, Hall D et al. The C-532T polymorphism of the angiotensinogen gene is associated with pulse pressure: a possible explanation for heterogeneity in genetic association studies of AGT and hypertension. Int J Epidemiol 2007; 36:1356-62.

Baker MT, Olson MJ, Wang Y, Ronnenberg WC Jr, Johnson JT, Brady AN. Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism. Drug Metab Dispos 1995; 23:60-4.

Baker SD, van Schaik RH, Rivory LP et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004; 10:8341-50.

Baker SD, Verweij J, Cusatis GA et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009; 85:155-63.

Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One 2010. doi:10. 1371/journal. pone. 0009570.

Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos 2009; 37:254-8.

Balabanov S, Gontarewicz A, Keller G et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCR-ABL-positive cells in vitro. PLoS One 2011. doi:10. 1371/journal. pone. 0019164.

Balakin KV, Ekins S, Bugrim A et al. Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos 2004; 32:1183-9.

Balakin KV, Ekins S, Bugrim A et al. Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates. Drug Metab Dispos 2004; 32:1111-20.

Balakumar P, Kaur J. Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc Toxicol 2009; 9:169-76.

Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 1999; 21:105-15.

Balasubramanian D, Scacheri PC. Functional studies of menin through genetic manipulation of the Men1 homolog in mice. Adv Exp Med Biol 2009; 668:105-15.

Balasubramanian M, Shield JP, Acerini CL et al. Pancreatic hypoplasia presenting with neonatal diabetes mellitus in association with congenital heart defect and developmental delay. Am J Med Genet A 2010; 152:340-6.

Balcerczak E, Panczyk M, Piaskowski S, Pasz-Walczak G, Sałagacka A, Mirowski M. ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 2010; 25:1167-76.

Balding J, Kane D, Livingstone W et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003; 48:1408-13.

Balducci C, Beeg M, Stravalaci M et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 2010; 107:2295-300.

Balic I, Graham ST, Troyer DA et al. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 2002; 168:2245-8.

Balistreri CR, Grimaldi MP, Vasto S et al. Association between the polymorphism of CCR5 and Alzheimer’s disease: results of a study performed on male and female patients from Northern Italy. Ann N Y Acad Sci 2006; 1089:454-61.

Baloira A, Vilariño C, Leiro V, Valverde D. Mutations in the gene encoding bone morphogenetic protein receptor 2 in patients with idiopathic pulmonary arterial hypertension. Arch Bronconeumol 2008; 44:29-34.

Baltes MR, Dubois JG, Hanocq M. Application to drug-food interactions of living cells as in vitro model expressing cytochrome P450 activity: enzyme inhibition by lemon juice. Talanta 2001; 54:983-7.

Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007; 320:331-43.

Balunas MJ, Su B, Riswan S et al. Isolation and characterization of Aromatase inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochem Lett 2009; 2:29-33.

Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997; 43:619-26.

Ball SE, Maurer G, Zollinger M, Ladona M, Vickers AE. Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans. Drug Metab Dispos 1992; 20:56-63.

Ball SE, Scatina J, Kao J et al. Population distribution and effects on drug metabolism of a genetic variant in the 5’ promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66:288-94.

Ballard JE, Prueksaritanont T, Tang C. Hepatic metabolism of MK-0457, a potent aurora kinase inhibitor: interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase. Drug Metab Dispos 2007; 35:1447-51.

Ballarè E, Persani L, Lania AG et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001; 86:3809-14.

Ballatori N, Fang F, Christian WV, Li N, Hammond CL. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am J Physiol Gastrointest Liver Physiol 2008; 295:179-86.

Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009; 390:191-214.

Ballent M, Lifschitz A, Virkel G, Mate L, Lanusse C. Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition. J Vet Pharmacol Ther 2010; 33:252-9.

Ballent M, Lifschitz A, Virkel G, Sallovitz J, Maté L, Lanusse C. Gender-related differences on P-glycoprotein-mediated drug intestinal transport in rats. J Pharm Pharmacol 2011; 63:619-626.

Balliet RM, Chen G, Dellinger RW, Lazarus P. UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility. Drug Metab Dispos 2010; 38:484-90.

Ballon N, Leroy S, Roy C et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 2006; 6:126-30.

Bamba Y, Yun YS, Kunugi A, Inoue H. Compounds isolated from Curcuma aromatica Salisb. inhibit human P450 enzymes. J Nat Med 2011; 65:583-7.

Bambha K, Kim WR, Rosen CB et al. Endothelial nitric oxide synthase gene variation associated with chronic kidney disease after liver transplant. Mayo Clin Proc 2010; 85:814-20.

Bamburowicz-Klimkowska M, Zywiec K, Potentas A, Szutowski M. Impact of the changes in P-glycoprotein activity on domperidone pharmacokinetics in rat plasma. Pharmacol Rep 2007; 59:752-6.

Ban H, Andoh A, Imaeda H et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 2010; 45:1014-21.

Ban S, Kondo T, Ishizuka M et al. Using microarray analysis to evaluate genetic polymorphisms involved in the metabolism of environmental chemicals. Fukuoka Igaku Zasshi 2007; 98:208-14.

Banaschewski T, Becker K, Scherag S, Franke B, Coghill D. Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur Child Adolesc Psychiatry 2010; 19:237-57.

Bandmann O, Nygaard TG, Surtees R, Marsden CD, Wood NW, Harding AE. Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet 1996; 5:403-6.

Bandulik S, Penton D, Barhanin J, Warth R. TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation. Horm Metab Res 2010; 42:450-7.

Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008; 86:1206-13.

Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT. Novel drug targets based on metallobiology of Alzheimer’s disease. Expert Opin Ther Targets 2010; 14:1177-97.

Banerjee I, Skae M, Flanagan SE et al. The contribution of rapid KATP channel gene mutation analysis to the clinical management of children with congenital hyperinsulinism. Eur J Endocrinol 2011; 164:733-40.

Banerjee S, A’Hern R, Detre S et al. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin Cancer Res 2010; 16:4178-87.

Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002; 41 Suppl 1:37-44.

Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002; 41 Suppl 1:29-35.

Banfield DK, MacGillivray RT. Partial characterization of vertebrate prothrombin cDNAs: amplification and sequence analysis of the B chain of thrombin from nine different species. Proc Natl Acad Sci USA 1992; 89:2779-83.

Bang L, Goa K. Oxcarbazepine: a review of its use in children with epilepsy. Paediatr Drugs 2003; 5:557-73.

Bang LM, Goa KL. Spotlight on oxcarbazepine in epilepsy. CNS Drugs 2004; 18:57-61.

Bangsi D, Zhou J, Sun Y et al. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol 2006; 24:21-7.

Banning AM. Respiratory depression following medication change from tramadol to morphine. Ugeskr Laeger 1999; 161:6500-1.

Bannister SC, Smith CA, Roeszler KN, Doran TJ, Sinclair AH, Tizard ML. Manipulation of estrogen synthesis alters MIR202* expression in embryonic chicken gonads. Biol Reprod 2011; 85:22-30.

Bansal I, Waghmare CK, Anand T, Gupta AK, Bhattacharya BK. Differential mRNA expression of acetylcholinesterase in the central nervous system of rats with acute and chronic exposure of sarin & physostigmine. J Appl Toxicol 2009; 29:386-94.

Bansal R, Guleria S, Ries C, Hartmann RW. Synthesis and antineoplastic activity of O-alkylated derivatives of 7-hydroximinoandrost-5-ene steroids. Arch Pharm 2010; 343:377-83.

Bansal R, Guleria S, Thota S, Hartmann RW, Zimmer C. Synthesis and biological evaluation of 16E-arylidenosteroids as cytotoxic and anti-aromatase agents. Chem Pharm Bull 2011; 59:327-31.

Bansal S, Liu CP, Sepuri NB et al. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J Biol Chem 2010; 285:24609-19.

Bansal SS, Vadhanam MV, Gupta RC. Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm Res 2011; 28:1121-30.

Bantis C, Heering P, Aker S, Kuhr N, Grabensee B, Ivens K. Influence of cytokine gene polymorphisms on IgA nephropathy. Ren Fail 2008; 2:135-40.

Bantis C, Heering PJ, Siekierka-Harreis M et al. Impact of aldosterone synthase gene C-344T polymorphism on IgA nephropathy. Ren Fail 2011; 33:393-7.

Bantis C, Heering PJ, Stangou M et al. Influence of aldosterone synthase gene C-344T polymorphism on focal segmental glomerulosclerosis. Nephrology 2011. doi:10. 1111/j. 1440-1797. 2011. 01497. x.

Bantis C, Ivens K, Kreusser W et al. Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy. Am J Nephrol 2004; 24:258-67.

Bantubungi K, Jacquard C, Greco A et al. Minocycline in phenotypic models of Huntington’s disease. Neurobiol Dis 2005; 18:206-17.

Banu H, Renuka N, Vasanthakumar G. Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies. Biochimie 2011; 93:1028-36.

Bányász I, Bokodi G, Vásárhelyi B et al. Genetic polymorphisms for vascular endothelial growth factor in perinatal complications. Eur Cytokine Netw 2006; 174:266-70.

Bao L, Haque A, Jackson K et al. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol 2011; 178:838-52.

Bapat B, Xia L, Madlensky L et al. The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. Am J Hum Genet 1996; 59:736-9.

Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 2001; 29:30-5.

Bapiro TE, Hasler JA, Ridderström M, Masimirembwa CM. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6. 17 (CYP2D6. 17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol 2002; 64:1387-98.

Baptista R, Rebelo M, Decq-Mota J et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis 2011; 10:48.

Baradaran-Rahimi H, Radvar M, Arab HR, Tavakol-Afshari J, Ebadian AR. Association of interleukin-1 receptor antagonist gene polymorphisms with generalized aggressive periodontitis in an Iranian population. J Periodontol 2010; 81:1342-6.

Baranczewski P, Möller L. Relationship between content and activity of cytochrome P450 and induction of heterocyclic amine DNA adducts in human liver samples in vivo and in vitro. Cancer Epidemiol Biomarkers Prev 2004; 13:1071-8.

Baranzini SE, Wang J, Gibson RA et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18:767-78.

Barash H, R Gross E, Edrei Y et al. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci USA 2010; 107:2207-12.

Barattin R, Perrotton T, Trompier D et al. Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1. Bioorg Med Chem 2010; 18:6265-74.

Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. Fundam Clin Pharmacol 2009; 23:423-5.

Barbalić M, Skarić-Jurić T, Cambien F et al. Gene polymorphisms of the renin-angiotensin system and early development of hypertension. Am J Hypertens 2006; 19:837-42.

Barbato E, Berger A, Delrue L et al. GLU-27 variant of beta2-adrenergic receptor polymorphisms is an independent risk factor for coronary atherosclerotic disease. Atherosclerosis 2007; 194:80-6.

Barbato E, Penicka M, Delrue L et al. Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy. Heart 2007; 93:856-61.

Barbaux S, Kluijtmans LA, Whitehead AS. Accurate and rapid “multiplex heteroduplexing” method for genotyping key enzymes involved in folate/homocysteine metabolism. Clin Chem 2000; 46:907-12.

Barberger-Gateau P, Samieri C, Féart C, Plourde M. Dietary Omega 3 polyunsaturated fatty acids and Alzheimer’s disease: interaction with Apolipoprotein E genotype. Curr Alzheimer Res 2011; 8:479-91.

Barbieri I, Pensa S, Pannellini T et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 2010; 70:2558-67.

Barbosa EJ, Palming J, Glad CA et al. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. J Clin Endocrinol Metab 2009; 94:639-44.

Barcelos AL, Chies R, Almeida SE et al. Association of CYP7A1 -278A>C polymorphism and the response of plasma triglyceride after dietary intervention in dyslipidemic patients. Braz J Med Biol Res 2009; 42:487-93.

Barclay ML, Sawyers SM, Begg EJ et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003; 13:627-32.

Bardag-Gorce F, Oliva J, Wong W et al. S-adenosylmethionine decreases the peak blood alcohol levels 3 h after an acute bolus of ethanol by inducing alcohol metabolizing enzymes in the liver. Exp Mol Pathol 2010; 89:217-21.

Bardag-Gorce F. Proteasome inhibitor treatment in alcoholic liver disease. World J Gastroenterol 2011; 17:2558-62.

Bardia A, Olson JE, Vachon CM et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 2011; 126:149-55.

Bardowell SA, Stec DE, Parker RS. Common variants of cytochrome P450 4F2 exhibit altered vitamin E-{omega}-hydroxylase specific activity. J Nutr 2010; 140:1901-6.

Barecki ME, Casciano CN, Johnson WW, Clement RP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos 2001; 29:1173-5.

Bareggi SR, Braida D, Pollera C et al. Effects of clioquinol on memory impairment and the neurochemical modifications induced by scrapie infection in golden hamsters. Brain Res 2009; 1280:195-200.

Bareggi SR, Mundo E, Dell’Osso B, Altamura AC. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol 2007; 3:741-53.

Barghorn S, Davies P, Mandelkow E. Tau paired helical filaments from Alzheimer’s disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry 2004; 43:1694-703.

Baririan N, Desager JP, Petit M, Horsmans Y. CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination. J Pharm Biomed Anal 2006; 40:211-4.

Baririan N, Horsmans Y, Desager JP et al. Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. J Clin Pharmacol 2005; 45:1434-41.

Baririan N, van Obbergh L, Desager JP et al. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet 2007; 46:261-70.

Barker ML, Hathaway LB, Arch DD et al. Hyper- and hypo-induction of cytochrome P450 activities with Aroclor 1254 and 3-methylcholanthrene in Cyp1a2(-/-) mice. Chem Biol Interact 2009; 182:220-6.

Barkhordari E, Rezaei N, Ansaripour B et al. Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol 2010; 30:74-9.

Barkin RL. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther 2007; 14:299-305.

Barnby G, Abbott A, Sykes N et al. Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT. Am J Hum Genet 2005; 76:950-66.

Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998; 32:70-7.

Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A, Modlin RL. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immun 1990; 145:149-54.

Baroja A, de la Hoz C, Álvarez A et al. Polyploidization and exit from cell cycle as mechanisms of cultured melanoma cell resistance to methotrexate. Life Sci 1998; 62:2275-82.

Baron JM, Goh LB, Yao D, Wolf CR, Friedberg T. Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping. J Pharmacol Exp Ther 2001; 296:351-8.

Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John’s wort and cyclosporine. Ann Pharmacother 2000; 34:1013-6.

Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010; 16:2702-8.

Barque JP, Abahamid A, Flinois JP, Beaune P, Bonaly J. Constitutive overexpression of immunoidentical forms of PCP-induced Euglena gracilis CYP-450. Biochem Biophys Res Commun 2002; 298:277-81.

Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 2010; 11:369-90.

Barragan E, Collado M, Cervera J et al. The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 2007; 31:947-53.

Barrio R, Bellanné-Chantelot C, Moreno JC et al. Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. J Clin Endocrinol Metab 2002; 87:2532-9.

Barron AM, Fuller SJ, Verdile G, Martins RN. Reproductive hormones modulate oxidative stress in Alzheimer’s disease. Antioxid Redox Signal 2006; 8:2047-59.

Barros SA, Srimaroeng C, Perry JL et al. Activation of protein kinase Czeta increases OAT1 (SLC22A6)- and OAT3 (SLC22A8)-mediated transport. J Biol Chem 2009; 284:2672-9.

Barroso I, Luan J, Wheeler E et al. Population-specific risk of type 2 diabetes conferred by HNF4A P2 promoter variants: a lesson for replication studies. Diabetes 2008; 57:3161-5.

Barry KH, Zhang Y, Lan Q et al. Genetic variation in metabolic genes, occupational solvent exposure, and risk of non-hodgkin lymphoma. Am J Epidemiol 2011; 173:404-13.

Barst RJ. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2007; 8:95-109.

Bart G, Heilig M, LaForge KS et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 2004; 9:547-9.

Bart G, Kreek MJ, Ott J et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005; 30:417-22.

Bartels AL, de Klerk OL, Kortekaas R, de Vries JJ, Leenders KL. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Curr Top Med Chem 2010; 10:1775-84.

Bartels LE, Hvas CL, Agnholt J, Dahlerup JF, Agger R. Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation. Int Immunopharmacol 2010; 10:922-8.

Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999; 13:154-68.

Barthel H, Gertz HJ, Dresel S et al. Cerebral amyloid-β PET with florbetaben ((18)F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10:424-35.

Bartik L, Whitfield GK, Kaczmarska M et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem 2010; 21:1153-61.

Bartley GE, Yokoyama W, Young SA et al. Hypocholesterolemic effects of hydroxypropyl methylcellulose are mediated by altered gene expression in hepatic bile and cholesterol pathways of male hamsters. J Nutr 2010; 140:1255-60.

Bartmann H, Fuest C, la Fougere C et al. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010; 51:1780-90.

Bartolomucci A, La Corte G, Possenti R et al. TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Nat Acad Sci USA 2006; 103:14584-9.

Bartolomucci A, Possenti R, Levi A, Pavone F, Moles A. The role of the vgf gene and VGF-derived peptides in nutrition and metabolism. Genes Nutr 2007; 2:169-80.

Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6:557-70.

Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res 2007; 174:19-36.

Bartsch R, Wenzel C, Zielinski CC, Steger GG. HER-2-positive breast cancer: hope beyond trastuzumab. BioDrugs 2007; 21:69-77.

Barwick JL, Quattrochi LC, Mills AS, Potenza C, Tukey RH, Guzelian PS. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol Pharmacol 1996; 50:10-6.

Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology 2006; 67:2170-5.

Basavarajappa MS, Craig ZR, Hernández-Ochoa I, Paulose T, Leslie TC, Flaws JA. Methoxychlor reduces estradiol levels by altering steroidogenesis and metabolism in mouse antral follicles in vitro. Toxicol Appl Pharmacol 2011; 253:161-9.

Basi GS, Hemphill S, Brigham EF et al. Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer’s disease. Alzheimers Res Ther 2010; 2:36.

Basic S, Hajnsek S, Bozina N et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008; 17:524-30.

Basmaison O, Rolland MO, Cochat P, Bozon D. Identification of 5 novel mutations in the AGXT gene. Hum Mutat 2000; 15:577.

Bass SE, Sienkiewicz P, Macdonald CJ et al. Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin Cancer Res 2009; 15:1964-72.

Bassiouny AR, Zaky A, Neenaa HM. Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol 2010; 9:410-8.

Basso AD, Doll RJ. Inhibition of cyclin-dependent kinases – a review of the recent patent literature. Recent Pat Anticancer Drug Discov 2006; 1:357-67.

Bastepe M, Jüppner H. GNAS locus and pseudohypoparathyroidism. Horm Res 2005; 63:65-74.

Bastepe M. The GNAS locus and pseudohypoparathyroidism. Adv Exp Med Biol 2008; 626:27-40.

Bastianetto S, Krantic S, Chabot JG, Quirion R. Possible involvement of programmed cell death pathways in the neuroprotective action of polyphenols. Curr Alzheimer Res 2011; 8:445-51.

Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol 2009; 124:1188-94.

Basu NK, Ciotti M, Hwang MS et al. Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Bio Chem 2004; 279:1429-41.

Basun H, Lind B, Nordberg M, Nordström M, Björkstén KS, Winblad B. Cadmium in blood in Alzheimer’s disease and non-demented subjects: results from a population-based study. Biometals 1994; 7:130-4.

Batar B, Güven M, Bariş S, Celkan T, Yildiz I. DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia. Leuk Res 2009; 33:759-63.

Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 2009; 46:67-74.

Bate C, Tayebi M, Diomede L, Salmona M, Williams A. Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biol 2008; 6:39.

Batel P, Houchi H, Daoust M, Ramoz N, Naassila M, Gorwood P. A haplotype of the DRD1 gene is associated with alcohol dependence. Alcohol Clin Exp Res 2008; 32:567-72.

Bates DE, Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother 2006; 40:1190-5.

Bates G, Mangiarini L, Mahal A, Davies S. Transgenic model of Huntingston’s disease. Hum Molec Genet 1997; 6:1633-7.

Bates SE, Zhan Z, Steadman K et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010; 148:256-67.

Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Hørder M, Brøsen K. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 1999; 48:395-401.

Batourina E, Gim S, Bello N et al. Vitamin A controls epithelial/mesenchymal interactions through Ret expression. Nat Genet 2001; 27:74-8.

Batra CM, Gupta N, Atwal G, Gupta V. Transient neonatal diabetes due to activating mutation in the ABCC8 gene encoding SUR1. Indian J Pediatr 2009; 76:1169-72.

Battino D, Croci D, Rossini A, Messina S, Mamoli D, Perucca E. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003; 44:923-9.

Battochio A, Mohammed S, Winthrop D et al. Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort. Am J Clin Pathol 2010; 133:149-55.

Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995; 39:305-11.

Baudhuin LM, Miller WL, Train L et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol 2010; 106:402-8.

Baudin B. Angiotensin I-converting enzyme gene polymorphism and drug response. Clin Chem Lab Med 2000; 38:853-6.

Baudin B. Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations. Pharmacogenomics 2002; 3:65-73.

Baudin B. Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol 2005; 90:277-82.

Bauer F, Kuntner C, Bankstahl JP et al. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem 2010; 18:5489-97.

Bauer M, Karch R, Neumann F et al. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab 2010; 30:510-5.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, Ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011. doi:10. 1136/bmj. d4588.

Bauerfeind A, Knoblauch H, Costanza MC et al. Concordant association of lipid gene variation with a combined HDL/LDL-cholesterol phenotype in two European populations. Hum Hered 2006; 61:123-31.

Bauerfeind I, Elling D, Heinemann V. Lapatinib in the treatment of hormone receptor-positive/ErbB2-positive breast cancer. Breast Care 2010; 5:13-15.

Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007; 75:75-83.

Baulac S, Gourfinkel-An I, Picard F et al. A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33. Am J Hum Genet 1999; 65:1078-85.

Baum CE, Ockers SB, English BC, Price DK, Sartor O, Figg WD. Androgen receptor sequence and variations in several common prostate cancer cell lines. Cancer Biol Ther 2010; 9:383-8.

Bauman JN, Frederick KS, Sawant A et al. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab Dispos 2008; 36:1016-29.

Baumann C, Davies B, Peters M, Kaufmann-Reiche U, Lessl M, Theuring F. AKR1B7 (mouse vas deferens protein) is dispensable for mouse development and reproductive success. Reproduction 2007; 134:97-109.

Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31:444-69.

Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol 1998; 13 Suppl 5:35-43.

Baumann P, Mandl-Weber S, Völkl A et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009; 8:366-75.

Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995; 10 Suppl 1:15-21.

Baumhäkel M, Kasel D, Rao-Schymanski RA et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001; 39:517-28.

Baune BT, Dannlowski U, Domschke K et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 2010; 67:543-9.

Baune BT, Hohoff C, Berger K et al. Association of the COMT Val158Met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008; 33:924-32.

Bavadekar SA, Hong SS, Lee SI, Miller DD, Feller DR. Bioisosteric phentolamine analogs as selective human alpha(2)- versus alpha(1)-adrenoceptor ligands. Eur J Pharmacol 2008; 590:53-60.

Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol 2011; 51:561-74.

Båvner A, Shafaati M, Hansson M et al. On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase. J Lipid Res 2010; 51:2722-30.

Bax DA, Gaspar N, Little SE et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 2009; 15:5753-61.

Baxter LC, Caselli RJ, Johnson SC, Reiman E, Osborne D. Apolipoprotein E epsilon4 affects new learning in cognitively normal individuals at risk for Alzheimer disease. Neurobiol Aging 2003; 24:947-52

Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. Am J Ophthal 2002; 133:135-7.

Bayne S, Li H, Jones ME et al. Estrogen deficiency reversibly induces telomere shortening in mouse granulosa cells and ovarian aging in vivo. Protein Cell 2011; 2:333-46.

Bazargani A, Khoramrooz SS, Kamali-Sarvestani E, Taghavi SA, Saberifiroozi M. Association between peroxisome proliferator-activated receptor-γ gene polymorphism (Pro12Ala) and Helicobacter pylori infection in gastric carcinogenesis. Scand J Gastroenterol 2010; 45:1162-7.

Bazo AP, Salvadori D Jr, Salvadori RA et al. DNA repair gene polymorphism is associated with the genetic basis of atherosclerotic coronary artery disease. Cardiovasc Pathol 2011; 20:9-15.

B’chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci 2009; 84:779-84.

Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000; 40:637-44.

Beamer BA, Yen CJ, Andersen RE et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47:1806-8.

Bearden DT, Neuhauser MM, Garey KW. Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy 2001; 21:1204-22.

Beauclair S, Formento P, Fischel JL et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 2007; 18:1335-41.

Beaumont KA, Newton RA, Smit DJ, Leonard JH, Stow JL, Sturm RA. Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. Hum Mol Genet 2005; 14:2145-54.

Beaver KM, DeLisi M, Vaughn MG, Barnes JC. Monoamine oxidase A genotype is associated with gang membership and weapon use. Compr Psychiatry 2010; 51:130-4.

Bebawy M, Chetty M. Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome. Curr Drug Metab 2009; 10:322-8.

Bebawy M, Rasmussen C, Sambasivam S, Bao S. Dietary nucleotide supplements in infant formula modify the expression of P-glycoprotein in the intestinal epithelium in vitro. Int J Vitam Nutr Res 2009; 79:381-7.

Bebia Z, Buch SC, Wilson JW et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004; 76:618-27.

Beck M, Brückner MK, Holzer M et al. Guinea-pig primary cell cultures provide a model to study expression and amyloidogenic processing of endogenous amyloid precursor protein. Neuroscience 2000; 95:243-54.

Becker C, Bray-French K, Drewe J. Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol 2010; 6:1437-44.

Becker LE, Koleganova N, Piecha G et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol 2011; 300:772-82.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics 2009; 10:1743-51.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9:242-7.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 2010; 19:75-81.

Becker RM, da Silva VK, Machado Fda S et al. Association between environmental quality, stress and APOE gene variation in fibromyalgia susceptibility determination. Rev Bras Reumatol 2010; 50:617-24.

Becker SL. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs 2003; 12:401-12.

Beckers MM, Ruven HJ, Haas FJ et al. Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. Eur J Intern Med 2010; 21:289-92.

Beckman DR, Hoganson G, Berlow S, Gilbert EF. Pathological findings in 5,10-methylene tetrahydrofolate reductase deficiency. Birth Defects Orig Artic Ser 1987; 23:47-64.

Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R et al. Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol 1999; 85:299-304.

Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86:250-6.

Becquemont L, Camus M, Eschwege V et al. Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. Fundam Clin Pharmacol 2000; 14:519-25.

Becquemont L, Chazouilleres O, Serfaty L et al. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther 2002; 71:488-95.

Becquemont L, Glaeser H, Drescher S et al. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin Pharmacol Ther 2006; 79:449-60.

Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Brentano C, Jaillon P. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999; 27:1068-73.

Beedanagari SR, Bebenek I, Bui P, Hankinson O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol Sci 2009; 110:61-7.

Beedanagari SR, Taylor RT, Bui P, Wang F, Nickerson DW, Hankinson O. Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes. Mol Pharmacol 2010; 78:608-16.

Beedanagari SR, Taylor RT, Hankinson O. Differential regulation of the dioxin-induced Cyp1a1 and Cyp1b1 genes in mouse hepatoma and fibroblast cell lines. Toxicol Lett 2010; 194:26-33.

Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003; 23:229-32.

Beedholm-Ebsen R, van de Wetering K, Hardlei T, Nexø E, Borst P, Moestrup SK. Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. Blood 2010; 115:1632-9.

Beeks E, Kessels AG, Kroon AA, van der Klauw MM, de Leeuw PW. Genetic predisposition to salt-sensitivity: a systematic review. J Hypertens 2004; 22:1243-9.

Beel AJ, Sakakura M, Barrett PJ, Sanders CR. Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer’s disease relationships? Biochim Biophys Acta 2010; 1801:975-82.

Been LF, Ralhan S, Wander GS et al. Variants in KCNQ1 increase type II diabetes susceptibility in South Asians: A study of 3,310 subjects from India and the US. BMC Med Genet 2011; 12:18.

Beghin D, Forestier F, Noël-Hudson MS et al. Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir. Eur J Obstet Gynecol Reprod Biol 2010; 152:55-9.

Begré S, von Bardeleben U, Ladewig D et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22:211-5.

Beher D, Fricker M, Nadin A et al. In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand. Biochemistry 2003; 42:8133-42.

Behre HM, Greb RR, Mempel A et al. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics 2005; 15:451-6.

Behrens A, Aguzzi A. Small is not beatiful: antagonizing functions for the prion protein PrP(C) and its homologue Dpl. Trends in Neurosci 2002; 25:150-4.

Bei T, Tilkeridis C, Garantziotis S et al. A novel, non-functional, COL1A1 polymorphism is not associated with lumbar disk disease in young male Greek subjects unlike that of the Sp1 site. Hormones 2008; 7:251-4.

Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1999; 37:529-47.

Beil W, Sewing KF, Kromer W. Basic aspects of selectivity of pantoprazole and its pharmacological actions. Drugs Today 1999; 35:753-64.

Beilke LD, Aleksunes LM, Holland RD et al. Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab Dispos 2009; 37:1035-45.

Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100:1052-7.

Beitelshees AL, Finck BN, Leone TC et al. Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes. Pharmacogenet Genomics 2010; 20:231-8.

Beitelshees AL, Johnson JA, Hames ML et al. Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. PLoS One 2010. doi:10. 1371/journal. pone. 0015180.

Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics J 2006; 6:174-8.

Belbin O, Carrasquillo MM, Crump M et al. Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease. Hum Genet 2011; 129:273-82.

Belenkov YN, Privalova EV, Kaplunova VY, Stambol’skiĭ DV, Fomin AA. Analysis of morpho-functional parameters of the heart and polymorphisms of renin-angiotensin-aldosterone system genes in patients with different variants of the course of hypertrophic cardiomyopathy. Kardiologiia 2010; 50:27-34.

Belfer I, Buzas B, Evans C et al. Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans. Eur J Hum Genet 2005; 13:341-51.

Belin de Chantemèle EJ, Retailleau K, Pinaud F et al. Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries. Arterioscler Thromb Vasc Biol 2008; 28:2216-24.

Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 2002; 62:6172-7.

Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998; 54:261-4.

Beltinger J, Haschke M, Kaufmann P, Michot M, Terracciano L, Krähenbühl S. Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin. Ann Pharmacother 2006; 40:767-70.

Bell DA, Taylor JA, Butler MA et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:1689-92.

Bell DW, Gore I, Okimoto RA et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005; 37:1315-6.

Bell EC, Ravis WR, Chan HM, Lin YJ. Lack of pharmacokinetic interaction between St. John’s wort and prednisone. Ann Pharmacother 2007; 41:1819-24.

Bell LN, Molleston JP, Morton MJ et al. Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. J Clin Gastroenterol 2011; 45:800-7.

Bell LN, Temm CJ, Saxena R et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg 2010; 251:1041-8.

Bellanger N, Orsoni A, Julia Z et al. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2011; 31:1675-81.

Bellanné-Chantelot C, Saint-Martin C, Ribeiro MJ et al. ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism. J Med Genet 2010; 47:752-9.

Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002; 42:1219-27.

Bellec G, Dréano Y, Lozach P, Ménez JF, Berthou F. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis 1996; 17:2029-34.

Bellili NM, Foucan L, Fumeron F et al. Associations of the -344 T>C and the 3097 G>A polymorphisms of CYP11B2 gene with hypertension, type 2 diabetes, and metabolic syndrome in a French population. Am J Hypertens 2010; 23:660-7.

Bellincampi L, Ballerini S, Bernardini S et al. Glutathione transferase P1 polymorphism in neuroblastoma studied by endonuclease restriction mapping. Clin Chem Lab Med 2001; 39:830-5.

Belloc C, Baird S, Cosme J et al. Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology 1996; 106:207-19.

Bellocq D, Molina J, Rathahao-Paris E, Taché S, Pierre F, Paris A. Metabolic bioactivation of oestradiol-17beta (E2beta) in mouse colon epithelial cells bearing ApcMin mutation. Steroids 2010; 75:665-75.

Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol 2009; 65:959-62.

Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 2004; 165:1643-52.

Bellusci CP, Rocco CA, Aulicino PC et al. MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission. AIDS 2010; 24:833-40.

Ben Dhifallah I, Karray EF, Sassi F, Hamzaoui K. Intercellular adhesion molecule 1 K469E gene polymorphism is associated with presence of skin lesions in Tunisian Behçet’s disease patients. Tissue Antigens 2010; 75:74-8.

Benayoun L, Granot E, Rizel L, Allon-Shalev S, Behar DM, Ben-Yosef T. Abetalipoproteinemia in Israel: evidence for a founder mutation in the Ashkenazi Jewish population and a contiguous gene deletion in an Arab patient. Molec Genet Metab 2007; 90:453-57.

Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases. Acta Oncol 2008; 47:1046-53.

Bendel SD, Bona R, Baker WL. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Adv Ther 2011; 28:460-72.

Benedetti F, Bernasconi A, Lorenzi C et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 2004; 355:37-40.

Benedetti F, Serretti A, Pontiggia A et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 2005; 376:51-5.

Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000; 14:301-19.

Benedetti MS, Whomsley R, Canning M. Drug metabolism in the paediatric population and in the elderly. Drug Discov Today 2007; 12:599-610.

Benedetto A, Squadrone S, Prearo M, Elia AC, Giorgi I, Abete MC. Evaluation of ABC efflux transporters genes expression in kidney of rainbow trout (Oncorhynchus mykiss) fed with melamine and cyanuric acid diets. Chemosphere 2011; 84:727-30.

Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003; 4:393-8.

Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004; 277:3-9.

Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999; 62:25-31.

Benetos A, Cambien F, Gautier S et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28:1081-4.

Benetton SA, Borges VM, Chang TK, McErlane KM. Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica 2004; 34:335-44.

Benetton SA, Fang C, Yang YO et al. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 2007; 22:78-87.

Bengtsson K, Melander O, Orho-Melander M et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001; 104:187-90.

Bengtsson K, Orho-Melander M, Lindblad U et al. Polymorphism in the angiotensin converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg Hypertension and diabetes project. J Hypertens 1999; 17:1569-75.

Benhamou S, Sarasin A. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 2005; 161:1-14.

Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 2002; 17:463-9.

Benites J, Valderrama JA, Taper H, Buc Calderon P. An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities. Invest New Drugs 2011; 29:760-7.

Benjafield AV, Wang WY, Morris BJ. No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. Am J Hypertens 2004; 17:624-8.

Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nat Genet 1996; 12:81-4.

Benjamin R, Leake A, McArthur FK et al. Propective effect of apoE e2 in Alzheimer’s disease. Lancet 1994; 334:473-4.

Benn M, Tybjærg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 2011; 103:508-19.

Bennet AM, Reynolds CA, Eriksson UK et al. Genetic association of sequence variants near AGER/NOTCH4 and dementia. J Alzheimers Dis 2011; 24:475-84.

Bennet C, Crawford F, Osborne A et al. Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer’s disease but is not causative. Am J Med Genet 1995; 60:1-6.

Bennett CL, Price DK, Kim S et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol 2002; 20:3599-604.

Bennett DA, Wilson RS, Schneider JA et al. Apolipoprotein E epsilon-4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology 2003; 60:246-52.

Bennett K, James C, Hussain K. Pancreatic β-cell KATP channels: Hypoglycaemia and hyperglycaemia. Rev Endocr Metab Disord 2010; 11:157-63.

Benod C, Subra G, Nahoum V et al. N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists. Bioorg Med Chem 2008; 16:3537-49.

Benoit E, Delatour P, Olivier L, Caldwell J. (-)-R-fenoprofen: formation of fenoprofenyl-coenzyme A by rat liver microsomes. Biochem Pharmacol 1995; 49:1717-20.

Benoit-Biancamano MO, Connelly J, Villeneuve L, Caron P, Guillemette C. Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos 2009; 37:322-9.

Benson AM, Hunkeler MJ, Talalay P. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 1980; 77:5216-20.

Benson C, White J, de Bono J et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96:29-37.

Benusiglio PR, Lesueur F, Luccarini C et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 2005; 7:204-9.

Benz-de Bretagne I, Respaud R, Vourc’h P et al. Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans. J Biomed Biotechnol 2011. doi:10. 1155/2011/498757.

Benzon Larsen S, Vogel U, Christensen J et al. Interaction between ADH1C Arg(272)Gln and alcohol intake in relation to breast cancer risk suggests that ethanol is the causal factor in alcohol related breast cancer. Cancer Lett 2010; 295:191-7.

Bepler G. Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720. Clin Lung Cancer 2007; 8:509-11.

Beraza N, Ofner-Ziegenfuss L, Ehedego H et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut 2011; 60:387-96.

Berbée JF, Vanmierlo T, Abildayeva K et al. Apolipoprotein CI knock-out mice display impaired memory functions. J Alzheimers Dis 2011; 23:567-98.

Berbel García A, Latorre Ibarra A, Porta Etessam J et al. Protease inhibitor-induced carbamazepine toxicity. Clin Neuropharmacol 2000; 23:216-8.

Berce V, Potocnik U. Association of Q551R polymorphism in the interleukin 4 receptor gene with nonatopic asthma in Slovenian children. Wien Klin Wochenschr 2010; 122 Suppl 2:11-8.

Berce V, Potocnik U. Functional polymorphism in CTLA4 gene influences the response to therapy with inhaled corticosteroids in Slovenian children with atopic asthma. Biomarkers 2010; 15:158-66.

Bercovitch L, Martin L, Chassaing N et al. Acquired pseudoxanthoma elasticum presenting after liver transplantation. J Am Acad Dermatol 2011; 64:873-8.

Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, Llerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003; 59:45-50.

Berecz R, Dorado P, de la Rubia A, Cáceres MC, Degrell I, Llerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr Drug Targets 2004; 5:573-9.

Bereczky Z, Kovács KB, Muszbek L. Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. Clin Chem Lab Med 2010; 48 Suppl 1:53-66.

Berg V, Lyche JL, Karlsson C et al. Accumulation and effects of natural mixtures of persistent organic pollutants (POP) in Zebrafish after two generations of exposure. J Toxicol Environ Health A 2011; 74:407-23.

Bergamaschi L, Leone MA, Fasano ME et al. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes Immun 2010; 11:173-80.

Berge KE, Leren TP. Mutations in APOA-I and ABCA1 in Norwegians with low levels of HDL cholesterol. Clin Chim Acta 2010; 411:2019-23.

Berge M, Chevalier P, Benammar M et al. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit 2009; 31:396-9.

Berge M, Guillemain R, Boussaud V et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009; 11:211-9.

Berge M, Guillemain R, Trégouet DA et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011; 67:253-60.

Bergen AA, Plomp AS, Schuurman EJ et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 2000; 25:228-31.

Bergen AW, van den Bree MB, Yeager M et al. Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa. Mol Psychiatry 2003; 8:397-406.

Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.

Berger K, Stogbauer F, Stoll M et al. The Glu298Asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum Genet 2007; 121:169-78.

Berger R, Mezey E, Clancy KP et al. Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis. Somat Cell Molec Genet 1995; 21:121-31.

Berges R, Gsur A, Feik E et al. Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample. World J Urol 2011; 29:143-8.

Berggren S, Gall C, Wollnitz N et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007; 4:252-7.

Berggren S, Lennernäs P, Ekelund M, Weström B, Hoogstraate J, Lennernäs H. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J Pharm Pharmacol 2003; 55:963-72.

Bergheim I, Bode C, Parlesak A. Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gastroenterol 2005; 5:34.

Bergheim I, Bode C, Parlesak A. Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol 2005; 5:4.

Bergheim I, Wolfgarten E, Bollschweiler E, Hölscher AH, Bode C, Parlesak A. Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma. World J Gastroenterol 2007; 13:997-1002.

Berginc K, Trdan T, Trontelj J, Kristl A. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Biopharm Drug Dispos 2010; 31:495-505.

Berginc K, Trontelj J, Kristl A. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab Pharmacokinet 2010; 25:307-13.

Berginc K, Žakelj S, Kristl A. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur J Nutr 2010; 49:373-84.

Bergman A, Einbeigi Z, Olofsson U et al. The western Swedish BRCA1 founder mutation 3171ins5; a 3. 7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 2001; 9:787-93.

Bergman A, Mistry GC, Luo WL et al. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007; 28:307-13.

Bergmann TK, Brasch-Andersen C, Gréen H et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011; 11:113-20.

Bergmann TK, Gréen H, Brasch-Andersen C et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011; 67:693-700.

Berle JØ, Steen VM, Aamo TO, Breilid H, Zahlsen K, Spigset O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004; 65:1228-34.

Berlin DS, Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. Pharmacogenet Genomics 2011; 21:308-11.

Berlin M, Ting PC, Vaccaro WD et al. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Bioorg Med Chem Lett 2006; 16:989-94.

Bermúdez-Fajardo A, Oviedo-Orta E. Influenza vaccination promotes stable atherosclerotic plaques in apoE knockout mice. Atherosclerosis 2011; 217:97-105.

Bernardi CC, Ribeiro Ede S, Cavalli IJ, Chautard-Freire-Maia EA, Souza RL. Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer. Cancer Genet Cytogenet 2010; 197:158-65.

Bernardi F, Castaman G, Redaelli R et al. Topologically equivalent mutations causing dysfunctional coagulation factors VII (294Ala→Val) and X (334Ser→Pro). Hum Mol Genet 1994; 3:1175-7.

Bernardi RE, Lattal KM. A role for alpha-adrenergic receptors in extinction of conditioned fear and cocaine conditioned place preference. Behav Neurosci 2010; 124:204-10.

Bernauer U, Heinrich-Hirsch B, Tönnies M, Peter-Matthias W, Gundert-Remy U. Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol Lett 2006; 164:278-88.

Berndt SI, Chatterjee N, Huang WY et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:165-8.

Berneburg M, Lehmann AR. Xeroderma pigmentosum and related disorders: defects in DNA repair and transcription. Adv Genet 2001; 43:71-102.

Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 2001; 15:211-8.

Bernsdorf A, Giessmann T, Modess C et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006; 61:440-50.

Bernstein D, Fajardo G, Zhao M et al. Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol 2005; 289:2441-9.

Bernstein RA, Gibbs M, Hunt Batjer H. Clinical diagnosis and successful treatment of inflammatory cerebral amyloid angiopathy. Neurocrit Care 2011; 14:453-5.

Berr C, Richard F, Dufouil C, Amant C, Alperovitch A, Amouyel P. Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurology 1998; 51:734-7.

Berr C, Vercambre MN, Bonenfant S, Manoux AS, Zins M, Goldberg M. Occupational exposure to solvents and cognitive performance in the GAZEL cohort: preliminary results. Dement Geriatr Cogn Disord 2010; 30:12-9.

Berrettini WH, Wileyto EP, Epstein L et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007; 61:111-8.

Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci USA 2003; 100:9034-8.

Berrougui H, Khalil A. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity. Rejuvenation Res 2009; 12:117-26.

Berry BW, Jamali F. Presystemic and systemic chiral inversion of R-(-)-fenoprofen in the rat. J Pharmacol Exp Ther 1991; 258:695-701.

Berry LM, Zhao Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2008; 2:51-9.

Berstein LM, Koskela A, Boyarkina MP, Adlercreutz H. Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin. Neoplasma 2010; 57:333-8.

Berstein LM, Yue W, Wang JP, Santen RJ. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat 2011; 128:109-17.

Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31:289-93.

Bertelli M, Cecchin S, Lapucci C et al. Study of the adenosinergic system in the brain of HPRT knockout mouse (Lesch-Nyhan disease). Clin Chim Acta 2006; 373:104-7.

Berthier MT, Paradis AM, Tchernof A et al. The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. J Hum Genet 2003; 48:14-9.

Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 1994; 47:1883-95.

Bertilsson G, Berkenstam A, Blomquist P. Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem Biophys Res Commun 2001; 280:139-44.

Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29:192-209.

Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 1997; 391:14-21.

Bertilsson L, Tybring G, Widén J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol 1997; 44:186-9.

Bertilsson PM, Olsson P, Magnusson KE. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J Pharm Sci 2001; 90:638-46.

Bertini I, Rosato A. Menkes disease. Cell Mol Life Sci 2008; 65:89-91.

Bertolino A, Caforio G, Blasi G et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res 2007; 95:253-5.

Bertolino A, Fazio L, Caforio G et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 2009; 132:417-25.

Bertolotti M, Gabbi C, Anzivino C et al. Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur J Clin Invest 2007; 37:501-8.

Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39:17-23.

Bertrand J, Treluyer JM, Panhard X et al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol 2009; 65:667-78.

Bertrand-Thiebault C, Ferrari L, Boutherin-Falson O et al. Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: linkage with varicosis. Clin Exp Pharmacol Physiol 2004; 31:295-301.

Berwaerts J, Cleton A, Herben V et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009; 42:158-63.

Besemer J, Harant H, Wang S et al. Selective inhibition of cotranslational translocation of vascular cell adhesion molecule 1. Nature 2005; 436:290-3.

Bessadok A, Garcia E, Jacquet H et al. Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins. J Biol Chem 2011; 286:3552-69.

Bessho Y, Oguri T, Ozasa H et al. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep 2009; 21:263-8.

Besson A, Salemi S, Deladoëy J et al. Short stature caused by a biologically inactive mutant growth hormone (GH-C53S). J Clin Endocrinol Metab 2005; 90:2493-9.

Bestue-Cardiel M, Sáenz de Cabezón-Alvarez A, Capablo-Liesa JL et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 2005; 65:144-6.

Beszłej JA, Grzesiak M, Milejski P. Acute dyskinetic syndrome during chloropromazine treatment of a female patient with CYP2D6 poor metabolism phenotype. Psychiatr Pol 2007; 41:495-501.

Betard C, Robitaille Y, Gee M et al. Apo E allele frequencies in Alzheimer’s disease, Lewy body dementia, Alzheimer’s disease with cerebrovascular disease and vascular dementia. Neuroreport 1994; 1893-6.

Bethke L, Webb E, Sellick G et al. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer 2007; 7:123.

Beukelaers P, Vandenbosch R, Caron N et al. Cdk6-dependent regulation of G(1)Length controls adult neurogenesis. Stem Cells 2011; 29:713-24.

Beulz-Riché D, Grudé P, Puozzo C et al. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 2005; 19:545-53.

Beulz-Riché D, Robert J, Riché C, Ratanasavanh D. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemother Pharmacol 2002; 49:274-80.

Beuten J, Gelfond JA, Franke JL et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2009; 18:1869-80.

Beutler E, Duparc S; G6PD Deficiency Working Group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 2007; 77:779-89.

Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95:8170-4.

Beutler E, Gelbart T, Pegelow C. Erythrocyte glutathione synthetase deficiency leads not only to glutathione but also to glutathione-S-transferase deficiency. J Clin Invest 1986; 77:38-41.

Bevelander GS, Pinto ES, Canario AV, Spanings T, Flik G. CYP27A1 expression in gilthead sea bream (Sparus auratus, L. ): effects of calcitriol and parathyroid hormone-related protein. J Endocrinol 2008; 196:625-35.

Beyeler C, Frey BM, Bird HA. Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol 1997; 36:54-8.

Beyer K, Lao JI, Álvarez XA, Cacabelos R. Different implications of APOE E4 in Alzheimer’s disease and vascular dementia in the Spanish population. Alzheimer Res 1996; 2:215-20.

Beyer K, Lao JI, Cacabelos R. Molecular genetics and genotyping in Alzheimer’s disease. Ann Psychiatry 1996; 6:173-87.

Beyer K, Lao JI, Carrato C et al. Cystathionine beta synthase as a risk factor for Alzheimer disease. Curr Alzheimer Res 2004; 1:127-33.

Beyer K, Lao-Villadóniga JI, Vecino-Bilbao B, Cacabelos R, de la Fuente-Fernández R. A novel point mutation in the GTP cyclohydrolase I gene in a Spanish family with hereditary progressive and dopa responsive dystonia. J Neurol Neurosurg Psychiatry 1997; 62:420-1.

Beyreuther K, Masters CL. Catching the culprit prion. Nature 1994; 370:419-20.

Bezerra FJ, do Vale NB, de Oliveira Macedo B, Rezende AA, Almeida MG. Evaluation of antioxidant parameters in rats treated with sevoflurane. Rev Bras Anestesiol 2010; 60:162-9, 93-7.

Bezzina CR, Verkerk AO, Busjahn A et al. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 2003; 59:27-36.

Bhagavath B, Carson SA. Ovulation induction in women with polycystic ovary syndrome: an update. Am J Obstet Gynecol 2011. doi:10. 1016/j. ajog. 2011. 06. 007.

Bhandaru M, Kempe DS, Rotte A, Rexhepaj R, Kuhl D, Lang F. Hyperaldosteronism, hypervolemia, and increased blood pressure in mice expressing defective APC. Am J Physiol Regul Integr Comp Physiol 2009; 297:571-5.

Bharadwaj D, Iino M, Kontoyianni M, Smith KJ, Foster DC, Kisiel W. Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity. J Biol Chem 1996; 271:30685-91.

Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 302:645-50.

Bharucha AE, Skaar T, Andrews CN et al. Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil 2008; 20:891-9.

Bhaskar V, Yin J, Mirza AM et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis 2011; 216:313-20.

Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7:51-8.

Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009; 284:10023-33.

Bhatnagar V, Garcia EP, O’Connor DT et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol 2010; 31:95-103.

Bhattacharjee A, Banerjee D, Mookherjee S et al. Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma. Mol Vis 2008; 14:841-50.

Bhattacharjee PS, Huq TS, Mandal TK et al. A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. PLoS One. 2011. doi:10. 1371/journal. pone. 0015905.

Bhattacharya S, Macdonald ST, Farthing CR. Molecular mechanisms controlling the coupled development of myocardium and coronary vasculature. Clin Sci 2006; 111:35-46.

Bhavani V, Srinivasulu M, Ahuja YR, Hasan Q. Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue. Cancer Biomark 2009; 5:207-13.

Bhave VS, Donthamsetty S, Latendresse JR, Cunningham ML, Mehendale HM. Secretory phospholipase A2-mediated progression of hepatotoxicity initiated by acetaminophen is exacerbated in the absence of hepatic COX-2. Toxicol Appl Pharmacol 2011; 251:173-80.

Bhuiyan AR, Chen W, Srinivasan SR et al. G-6A polymorphism of angiotensinogen gene modulates the effect of blood pressure on carotid intima-media thickness. The Bogalusa Heart Study. Am J Hypertens 2007; 20:1073-8.

Bhuiyan MJ, Do HV, Mun S et al. Hypocholesterolemic and hypoglycemic effects of enzymatically modified carbohydrates from rice in high-fat-fed C57BL/6J mice. Mol Nutr Food Res 2011; 55 Suppl 2:214-26.

Bhuiyan ZA, van den Berg MP, van Tintelen JP et al. Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation 2007; 116:1569-76.

Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM. Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir. Ann Pharmacother 2007; 41:1306-9.

Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res 2011; 71:1825-35.

Bialecka M, Klodowska-Duda G, Honczarenko K et al. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson’s disease. Parkinsonism Relat Disord 2007; 13:224-9.

Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 2010; 1804:1405-12

Bianchi A, Giustina A, Cimino V et al. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 2009; 94:2015-22.

Bianchino G, Cittadini A, Grieco V et al. Polymorphisms of the CYP1A1, CYP2E1 and XRCC1 genes and cancer risk in a Southern Italian population: a case-control study. Anticancer Res 2011; 31:1359-65.

Biasiotto G, Goldwurm S, Finazzi D et al. HFE gene mutations in a population of Italian Parkinson’s disease patients. Parkinsonism Relat Disord 2008; 14:426-30.

Bible KC, Lensing JL, Nelson SA et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11:5935-41.

Bidlack WR, Brown RC, Mohan C. Nutritional parameters that alter hepatic drug metabolism, conjugation, and toxicity. Fed Proc 1986; 45:142-8.

Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003; 56:305-14.

Bidstrup TB, Damkier P, Olsen AK, Ekblom M, Karlsson A, Brøsen K. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol 2006; 61:49-57.

Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Brøsen K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 2004; 60:109-14.

Bidwell LC, Garrett ME, McClernon FJ et al. A preliminary analysis of interactions between genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of young adults. Nicotine Tob Res 2011. doi:10. 1093/ntr/ntr125.

Bièche I, Narjoz C, Asselah T et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007; 17:731-42.

Biegon A, Kim SW, Alexoff DL et al. Unique distribution of aromatase in the human brain: in vivo studies with PET and [N-methyl-11C]vorozole. Synapse 2010; 64:801-7.

Biegon A, Kim SW, Logan J, Hooker JM, Muench L, Fowler JS. Nicotine blocks brain estrogen synthase (aromatase): in vivo positron emission tomography studies in female baboons. Biol Psychiatry 2010; 67:774-7.

Bielarczyk H, Tomaszewicz M, Madziar B, Cwikowska J, Pawełczyk T, Szutowicz A. Relationships between cholinergic phenotype and acetyl-CoA level in hybrid murine neuroblastoma cells of septal origin. J Neurosci Res 2003; 73:717-21.

Bieler CA, Arlt VM, Wiessler M, Schmeiser HH. DNA adduct formation by the environmental contaminant 3-nitrobenzanthrone in V79 cells expressing human cytochrome P450 enzymes. Cancer Lett 2003; 200:9-18.

Bielohuby M, Roemmler J, Manolopoulou J et al. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice. Exp Biol Med 2009; 234:1002-9.

Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Wang C, Huang Y. C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice. Proc Natl Acad Sci USA 2011; 108:4236-41.

Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007; 8:1221-8.

Bierman WF, Scheffer GL, Schoonderwoerd A et al. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 2010; 65:1672-80.

Biffi A, Plourde A, Shen Y et al. Screening for familial APP mutations in sporadic cerebral amyloid angiopathy. PLoS One 2010. doi:10. 1371/journal. pone. 0013949.

Biffi A, Sonni A, Anderson CD et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 2010; 68:934-43.

Biggs JS, Wan J, Cutler NS et al. Transcription factor binding to a putative double E-box motif represses CYP3A4 expression in human lung cells. Mol Pharmacol 2007; 72:514-25.

Bigler J, Sibert JG, Poole EM, Carlson CS, Potter JD, Ulrich CM. Polymorphisms predicted to alter function in prostaglandin E2 synthase and prostaglandin E2 receptors. Pharmacogenet Genomics 2007; 17:221-7.

Bijl MJ, Luijendijk HJ, van den Berg JF et al. Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. Pharmacogenomics 2009; 10:541-7.

Bijl MJ, van Schaik RH, Lammers LA et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009; 118:125-30.

Bijl MJ, Visser LE, Hofman A et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008; 65:558-64.

Bijl MJ, Visser LE, van Schaik RH et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 2009; 85:45-50.

Bijl N, van Roomen CP, Triantis V et al. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 2009; 49:637-45.

Bijland S, Rensen PC, Pieterman EJ et al. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden. CETP mice. Toxicol Sci 2011; 123:290-303.

Bilbao E, Raingeard D, de Cerio OD et al. Effects of exposure to Prestige-like heavy fuel oil and to perfluorooctane sulfonate on conventional biomarkers and target gene transcription in the thicklip grey mullet Chelon labrosus. Aquat Toxicol 2010; 98:282-96.

Bilgi N, Bell K, Ananthakrishnan AN, Atallah E. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 2010; 44:926-8.

Billestrup N, Swanson LW, Vale W. Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA 1986; 83:6854-7.

Billet S, Bardin S, Verp S et al. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest 2007; 117:1914-25.

Binder EB, Bradley RG, Liu W et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008; 299:1291-305.

Binder EB, Salyakina D, Lichtner P et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36:1319-25.

Bingham TC, Fisher EA, Parathath S, Reiss AB, Chan ES, Cronstein BN. A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux. J Leukoc Biol 2010; 87:683-90.

Bingham TC, Parathath S, Tian H et al. Cholesterol 27-hydroxylase but not Apolipoprotein apoE contributes to A(2A) adenosine receptor stimulated reverse cholesterol transport. Inflammation 2011. doi:10. 1007/s10753-010-9288-y.

Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A. Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. Xenobiotica 2010; 40:55-61.

Biolo A, Clausell N, Santos KG et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 2008; 102:726-32.

Bird MG, Wetmore BA, Letinski DJ et al. Influence of toluene co-exposure on the metabolism and genotoxicity of benzene in mice using continuous and intermittent exposures. Chem Biol Interact 2010; 184:233-9.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2009; CD001191.

Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006: CD005593.

Birmann BM, Tamimi RM, Giovannucci E et al. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2009; 18:282-8.

Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320:1731-5.

Bis JC, Smith NL, Psaty BM et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003; 16:1011-7.

Bisaga A, Kos T, Wójcikowski J, Daniel WA, Popik P. Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice. Drug Alcohol Depend 2008; 95:147-51.

Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 2004; 16 Suppl 1:34-7.

Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA. Iron: a pathological mediator of Alzheimer disease? Dev Neurosci 2002; 24:184-7.

Bishop JR, Bishop DL. Iloperidone for the treatment of schizophrenia. Drugs Today 2010; 46:567-79.

Bishop JR, Ellingrod VL, Moline J, Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 2005; 77:253-60.

Bishop JR, Miller DD, Ellingrod VL, Holman T. Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia. Hum Psychopharmacol 2011. doi:10. 1002/hup. 1163.

Bistrup C, Nielsen FT, Jeppesen UE, Dieperink H. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol Dial Transplant 2001; 16:373-7.

Biundo R, Gardini S, Caffarra P et al. Influence of APOE status on lexical-semantic skills in mild cognitive impairment. J Int Neuropsychol Soc 2011; 17:1-8.

Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009:461-76.

Bjelajac A, Goo AK, Weart CW. Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors. Ann Pharmacother 1996; 30:1304-15.

Bjork JA, Lau C, Chang SC, Butenhoff JL, Wallace KB. Perfluorooctane sulfonate-induced changes in fetal rat liver gene expression. Toxicology 2008; 251:8-20.

Björkhem I, Hansson M. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem Biophys Res Commun 2010; 396:46-9.

Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005; 59:691-704.

Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 2006; 45:1-11.

Bjørnerheim R, Frøysaker T, Hansson V. Effects of chronic amiodarone treatment on human myocardial beta adrenoceptor density and adenylate cyclase response. Cardiovasc Res 1991; 25:503-9.

Blaas L, Kornfeld JW, Schramek D et al. Disruption of the growth hormone-signal transducer and activator of transcription 5-insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology 2010; 51:1319-26.

Black JL, Litzow MR, Hogan WJ et al. Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. Leuk Res 2011. doi:10. 1016/j. leukres. 2011. 06. 020.

Black MP, Balthazart J, Baillien M, Grober MS. Rapid increase in aggressive behavior precedes the decrease in brain aromatase activity during socially mediated sex change in Lythrypnus dalli. Gen Comp Endocrinol 2011; 170:119-24.

Blacker D, Laird NM, Wilcox MA et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19:357-60.

Blagodatskikh KA, Evdokimova MA, Agapkina IuV et al. Gene IL6 G(-174)C and gene IL10 G(-1082)A polymorphisms are associated with unfavourable outcomes in patients with acute coronary syndrome. Mol Biol 2010; 44:839-46.

Blagojevic A, Delaney JA, Lévesque LE, Dendukuri N, Boivin JF, Brophy JM. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Pharmacoepidemiol Drug Saf 2009; 18:362-9.

Blaisdell J, Jorge-Nebert LF, Coulter S et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14:527-37.

Blaisdell J, Mohrenweiser H, Jackson J et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002; 12:703-11.

Blake JA, Pritchard M, Ding S et al. Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett 1996; 397:210-4.

Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 2006; 60:717-23.

Blake MJ, Gaedigk A, Pearce RE et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007; 81:510-6.

Blakely EL, Trip SA, Swalwell H et al. A new mitochondrial transfer RNAPro gene mutation associated with myoclonic epilepsy with ragged-red fibers and other neurological features. Arch Neurol 2009; 66:399-402.

Blakemore AI, Cox A, Gonzalez AM et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996; 97:369-74.

Blakey GE, Lockton JA, Perrett J et al. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br J Clin Pharmacol 2004; 57:162-9.

Blanco JG, Edick MJ, Hancock ML et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002; 12:605-11.

Blanco JG, Harrison PL, Evans WE, Relling MV. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 2000; 28:379-82.

Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005; 70:1096-103.

Blando JM, Carbajal S, Abel E et al. Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice. Neoplasia 2011; 13:254-65.

Blank MC, Stefanescu RN, Masuda E et al. Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005; 117:220-7.

Blanpain C, Lee B, Tackoen M et al. Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 2000; 96:1638-45.

Blanpain C, Libert F, Vassart G, Parmentier M. CCR5 and HIV infection. Receptors Channels 2002; 8:19-31.

Blasi G, Bertolino A. Imaging genomics and response to treatment with antipsychotics in schizophrenia. NeuroRx 2006; 3:117-30.

Blasko I, Kemmler G, Jungwirth S et al. Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors. J Neural Transm 2011; 118:663-72.

Bleasby K, Castle JC, Roberts CJ et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006; 36:963-88.

Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther 2005; 314:923-31.

Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38:667-78.

Bleecker ER, Nelson HS, Kraft M et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181:676-87.

Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370:2118-25.

Bleecker ER, Yancey SW, Baitinger LA et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809-16.

Blevins-Primeau AS, Sun D, Chen G et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009; 69:1892-900.

Bleyer AJ, Zivná M, Hulková H et al. Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone. Clin Nephrol 2010; 74:411-22.

Bliek BJ, van Schaik RH, van der Heiden IP et al. Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. Am J Med Genet A 2009; 149:2088-92.

Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, Wurst W. Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 1996; 34:51-5.

Bloch B, Reshef A, Cohen T et al. Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. Psychiatry Res 2010; 175:38-42.

Blokzijl H, van der Borght S, Bok LI et al. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 2007; 13:710-20.

Blom TS, Linder MD, Snow K et al. Defective endocytic trafficking of NPC1 and NPC2 underlying infantile Niemann-Pick type C disease. Hum Mol Genet 2003; 12:257-72.

Blomberg Jensen M, Andersen CB, Nielsen JE et al. Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J Steroid Biochem Mol Biol 2010; 121:376-82.

Blomberg Jensen M, Nielsen JE, Jørgensen A et al. Vitamin D receptor and vitamin D metabolizing enzymes are expressed in the human male reproductive tract. Hum Reprod 2010; 25:1303-11.

Blonk MI, van der Velde N, van den Bemt PM, van Schaik RH, van der Cammen TJ. CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people. Pharm World Sci 2010; 32:26-9.

Bloom J, Hinrichs AL, Wang JC et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics 2011; 21:403-16.

Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol 2011; 7:715-26.

Blum S, Milman U, Shapira C et al. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol 2008; 28:18-20.

Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29:769-84.

Blume N, Leonard J, Xu ZJ, Watanabe O, Remotti H, Fishman J. Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells. Arch Biochem Biophys 2000; 381:191-204.

Boada M, Antunez C, López-Arrieta J et al. Estrogen receptor alpha gene variants are associated with Alzheimer’s disease. Neurobiol Aging 2010. doi:10. 1016/j. neurobiolaging. 2010. 06. 016.

Board PG, Shaw DC. Determination of the amino acid substitution in human prothrombin type 3 (157 Glu leads to Lys) and the localization of a third thrombin cleavage site. Br J Haematol 1983; 54:245-54.

Bobrowska-Hägerstrand M, Wróbel A, Rychlik B, Ohman I, Hägerstrand H. Flow cytometric monitoring of multidrug drug resistance protein 1 (MRP1/ABCC1) -mediated transport of 2’,7’-bis-(3-carboxypropyl)-5-(and-6)-carboxyfluorescein (BCPCF) into human erythrocyte membrane inside-out vesicles. Mol Membr Biol 2007; 24:485-95.

Bocca C, Bozzo F, Bassignana A, Miglietta A. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 2011; 350:59-70.

Bock KW, Schrenk D, Forster A et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4:209-18.

Boctor AM, Eickholt M, Pugsley TA. Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med 1986; 23:229-38.

Bochud M, Eap CB, Maillard M et al. Association of ABCB1 genetic variants with renal function in Africans and in Caucasians. BMC Med Genomics 2008; 1:21.

Bochud PY, Chien JW, Marr KA et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766-77.

Bode KA, Donner MG, Leier I, Keppler D. Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol 2002; 64:151-8.

Bodin K, Bretillon L, Aden Y et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 2001; 276:38685-9.

Bodin K, Lindbom U, Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. Biochim Biophys Acta 2005; 1687:84-93.

Bodin L, Perdu J, Diry M, Horellou MH, Loriot MA. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 2008; 6:1436-9.

Bodin L, Verstuyft C, Tregouet DA et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Clin Pharmacol Ther 2007; 2:185-93.

Boeckmann L, Nickel AC, Kuschal C et al. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. Melanoma Res 2011; 21:206-16.

Boeckmann L, Schirmer M, Rosenberger A et al. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians. Pharmacogenet Genomics 2009; 19:760-9.

Boehnke M, Conneally P, Lange K. Two models for a maternal factor in the inheritance of Huntington disease. Am J Hum Genet 1983; 35:845-60.

Boek-Dohalská L, Hodek P, Sulc M, Stiborová M. alpha-Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem Biol Interact 2001; 138:85-106.

Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist 2011; 16:800-10.

Bogaards JJ, van Ommen B, Wolf CR, van Bladeren PJ. Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes. Toxicol Appl Pharmacol 1995; 132:44-52.

Bogaards JJ, Venekamp JC, van Bladeren PJ. The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome P450 enzymes, compared to mouse and rat liver microsomes. Chem Biol Interact 1996; 102:169-82.

Bogachev O, Majdalawieh A, Pan X, Zhang L, Ro HS. AEBP1, a novel macrophage proinflammatory mediator, over-expression promotes and ablation attenuates atherosclerosis in ApoE(-)(/)(-) and LDLR(-)(/)(-) mice. Mol Med 2011; 17:1056-64.

Bogard C, Daveau M, Deybach JC et al. Heme and acute inflammation role in vivo of heme in the hepatic expression of positive acute-phase reactants in rats. Eur J Biochem 1999; 261:190-6.

Bogman K, Silkey M, Chan SP, Tomlinson B, Weber C. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients. Eur J Clin Pharmacol 2010; 66:1005-15.

Bogner JR, Lutz B, Klein HG, Pollerer C, Troendle U, Goebel FD. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med 2004; 5:264-72.

Bogush TA, Dudko EA, Bogush EA, Kirsanov VIu, Antonov VG. Glutoxime-an inhibitor of multiple drug resistance phenotype associated with Pgp expression. Antibiot Khimioter 2010; 55:18-23.

Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem 2003; 278:36688-98.

Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007; 27:1425-39.

Bohanec Grabar P, Grabnar I, Rozman B et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos 2009; 37:2061-8.

Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64:871-6.

Bohets H, Lavrijsen K, Hendrickx J et al. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol 2000; 129:1655-67.

Böhmer G, Gleiter CH, Hünnemeyer A, Lahu G, Bethke TD. Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. Int J Clin Pharmacol Ther 2011; 49:451-60.

Böhmer GM, Drollmann A, Gleiter CH, Nave R. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide. Clin Pharmacokinet 2008; 47:343-9.

Böhmer GM, Gleiter CH, Mörike K, Nassr N, Walz A, Lahu G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol 2011; 51:594-602.

Bohn M, Berge KE, Bakken A, Erikssen J, Berg K. Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction. Clin Genet 1993; 44:298-301.

Bohnenstengel F, Hofmann U, Eichelbaum M, Kroemer HK. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol 1996; 51:297-301.

Bois C, Delalande C, Nurmio M et al. Age- and cell-related gene expression of aromatase and estrogen receptors in the rat testis. J Mol Endocrinol 2010; 45:147-59.

Bojanic DD, Tarr PT, Gale GD et al. Differential expression and function of ABCG1 and ABCG4 during development and aging. J Lipid Res 2010; 51:169-81.

Bokesch HR, Cartner LK, Fuller RW et al. Inhibition of ABCG2-mediated drug efflux by naphthopyrones from marine crinoids. Bioorg Med Chem Lett 2010; 20:3848-50.

Bolbrinker J, Beige J, Huber M et al. Role of CYP2C9 genetic variants for salt sensitivity and the regulation of the renin-angiotensin-aldosterone system in normotensive men. J Hypertens 2011; 29:56-61.

Bolk GS, Salomon R, Pelet A et al. Segregation at three loci explains familial and population risk in Hirschsprung disease. Nat Genet 2002; 31:89-93.

Bolognin S, Messori L, Drago D, Gabbiani C, Cendron L, Zatta P. Aluminum, copper, iron and zinc differentially alter amyloid-Aβ(1-42) aggregation and toxicity. Int J Biochem Cell Biol 2011; 43:877-85.

Bolt HM, Selinski S, Dannappel D, Blaszkewicz M, Golka K. Re-investigation of the concordance of human NAT2 phenotypes and genotypes. Arch Toxicol 2005; 79:196-200.

Bolt HM. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer’s pioneering ideas to modern concepts. Drug Metab Rev 2004; 36:497-509.

Bolufer P, Barragan E, Collado M, Cervera J, López JA, Sanz MA. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res 2006; 30:1471-91.

Bolufer P, Collado M, Barragán E et al. The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica 2007; 92:308-14.

Bolufer P, Collado M, Barragan E et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 2007; 136:590-6.

Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing’s syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004; 38:46-9.

Bombail V, Taylor K, Gibson GG, Plant N. Role of Sp1, C/EBP alpha, HNF3, and PXR in the basal- and xenobiotic-mediated regulation of the CYP3A4 gene. Drug Metab Dispos 2004; 32:525-35.

Bomsien S, Aderjan R, Mattern R, Skopp G. Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes. Eur J Clin Pharmacol 2006; 62:639-43.

Bomsien S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol 2007; 63:821-7.

Bonagura TW, Zhou H, Babischkin JS, Pepe GJ, Albrecht ED. Expression of P-450 aromatase, estrogen receptor α and β, and α-inhibin in the fetal baboon testis after estrogen suppression during the second half of gestation. Endocrine 2011; 39:75-82.

Bonapace G, Concolino D, Formicola S, Strisciuglio P. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 2003; 40:913-7.

Bonaventure P, Umans L, Bakker MH et al. Humanization of mouse 5-hydroxytryptamine1B receptor gene by homologous recombination: in vitro and in vivo characterization. Mol Pharmacol 1999; 56:54-67.

Bondiolotti G, Sala M, Pollera C et al. Pharmacokinetics and distribution of clioquinol in golden hamsters. J Pharm Pharmacol 2007; 59:387-93.

Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 1996; 128:421-5.

Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 2002; 35:50-6.

Bongaerts BW, de Goeij AF, Wouters KA et al. Alcohol consumption, alcohol dehydrogenase 1C (ADH1C) genotype, and risk of colorectal cancer in the Netherlands Cohort Study on diet and cancer. Alcohol 2011; 45:217-25.

Boni J, Abbas R, Leister C et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol 2009; 64:263-70.

Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol 2007; 47:1430-9.

Boni JP, Hug B, Leister C, Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol 2009; 36 Suppl 3:18-25.

Boni JP, Leister C, Burns J, Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008; 98:1797-802.

Boni R, Vortmeyer AO, Pack S et al. Somatic mutations of the MEN1 tumor suppressor gene detected in sporadic angiofibromas. J Invest Derm 1998; 111:539-40.

Bonkovsky HL, Naishadham D, Lambrecht RW et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006; 131:1440-51.

Bonn B, Masimirembwa CM, Aristei Y, Zamora I. The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition. Drug Metab Dispos 2008; 36:2199-210.

Bonn B, Masimirembwa CM, Castagnoli N Jr. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. Drug Metab Dispos 2010; 38:187-99.

Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 1996; 49:305-8.

Bonnabry P, Sievering J, Leemann T, Dayer P. Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions. Eur J Clin Pharmacol 1999; 55:341-7.

Bonnardeaux A, Davies E, Jeunemaitre X et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24:63-9.

Bonnefond A, Durand E, Sand O et al. Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome. PLoS One 2010. doi:10. 1371/journal. pone. 0013630.

Bonner-Jackson A, Okonkwo O, Tremont G; the Alzheimer’s Disease Neuroimaging Initiative. Apolipoprotein E ε2 and Functional Decline in Amnestic Mild Cognitive Impairment and Alzheimer Disease. Am J Geriatr Psychiatry 2011; 19:607-17.

Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003; 9:97-140.

Bonnycastle LL, Yu CE, Wijsman EM et al. The c-fos gene and early-onset familial Alzheimer’s disease. Neurosci Lett 1993; 160:33-6.

Bono M, Cases A, Calls J et al. Effect of antihypertensive treatment on the increased beta 2-adrenoceptor density in patients with essential hypertension. Am J Hypertens 1995; 8:487-93.

Bonomini F, Rodella LF, Moghadasian M, Lonati C, Coleman R, Rezzani R. Role of apolipoprotein E in renal damage protection. Histochem Cell Biol 2011; 135:571-9.

Bonora-Centelles A, Jover R, Mirabet V et al. Sequential hepatogenic transdifferentiation of adipose tissue-derived stem cells: relevance of different extracellular signaling molecules, transcription factors involved and expression of new key marker genes. Cell Transplant 2009; 18:1319-40.

Bönsch D, Lederer T, Reulbach U, Hothorn T, Kornhuber J, Bleich S. Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence. Hum Mol Genet 2005; 14:967-71.

Bonvicini C, Minelli A, Scassellati C et al. Serotonin transporter gene polymorphisms and treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:934-9.

Boobis AR, McKillop D, Robinson DT, Adams DA, McCormick DJ. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica 1998; 28:493-506.

Boocock DJ, Brown K, Gibbs AH, Sánchez E, Turteltaub KW, White IN. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002; 23:1897-901.

Boon WC, Horne MK. Aromatase and its inhibition in behaviour, obsessive compulsive disorder and parkinsonism. Steroids 2011; 76:816-9.

Boquoi A, Chen T, Enders GH. Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032. Cancer Prev Res 2009; 2:800-6.

Boraska Jelavić T, Barisić M, Drmic Hofman I et al. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006; 70:156-60.

Borg A, Isola J, Chen J et al. Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer 2000; 85:796-800.

Borgaonkar DS, Schmidt LC, Martin SE et al. Linkage of late-onset Alzheimer’s disease with apolipoprotein E type 4 on chromosome 19. Lancet 1993; 342:625.

Börgel J, Bulut D, Hanefeld C et al. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC Cardiovasc Disord 2008; 8:41.

Borggreve SE, Hillege HL, Wolffenbuttel BHR et al. The effect of cholesterol ester transfer protein -629C-A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J Clin Endocr Metab 2005; 90:4198-202.

Borghese B, Barbaux S, Mondon F et al. Research resource: genome-wide profiling of methylated promoters in endometriosis reveals a subtelomeric location of hypermethylation. Mol Endocrinol 2010; 24:1872-85.

Borgiani P, Ciccacci C, Forte V et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009; 10:261-6.

Boriani G, Biffi M, Diemberger I, Domenichini G, Marziali A, Martignani C. Atrial fibrillation: Adverse effects of “pill-in-the-pocket” treatment and propafenone-carvedilol interaction. Int J Cardiol 2010; 140:242-3.

Borkowska E, Binka-Kowalska A, Constantinou M, Nawrocka A, Matych J, Kałuzewski B. P53 mutations in urinary bladder cancer patients from Central Poland. J Appl Genet 2007; 48:177-83.

Borlak J, Walles M, Levsen K, Thum T. Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. Drug Metab Dispos 2003; 31:888-91.

Borlak J, Zwadlo C. Expression of drug-metabolizing enzymes, nuclear transcription factors and ABC transporters in Caco-2 cells. Xenobiotica 2003; 33:927-43.

Borlak JT, Harsany V, Schneble H, Haegele KD. pNAT and CYP2D6 gene polymorphism in epileptic patients. Biochem Pharmacol 1994; 48:1717-20.

Borobia AM, Novalbos J, Guerra-López P et al. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res 2009; 59:393-8.

Borowiec M, Liew CW, Thompson R et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci USA 2009; 106:14460-5.

Borozdenkova S, Smith J, Marshall S, Yacoub M, Rose M. Identification of ICAM-1 polymorphism that is associated with protection from transplant associated vasculopathy after cardiac transplantation. Hum Immunol 2001; 62:247-55.

Borrelli F, Izzo AA. Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009; 11:710-27.

Borroni B, Grassi M, Archetti S et al. Genetic background predicts poor prognosis in frontotemporal lobar degeneration. Neurodegener Dis 2011; 8:289-95.

Borska S, Sopel M, Chmielewska M, Zabel M, Dziegiel P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010; 15:857-70.

Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92:1295-302.

Bort R, Gómez-Lechón MJ, Castell JV, Jover R. Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes. Arch Biochem Biophys 2004; 426:63-72.

Bort R, Macé K, Boobis A, Gómez-Lechón MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999; 58:787-96.

Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks. Prescrire Int 2006; 15:98-100.

Bosco P, Caraci F, Copani A et al. The CDC2 I-G-T haplotype associated with the APOE epsilon4 allele increases the risk of sporadic Alzheimer’s disease in Sicily. Neurosci Lett 2007; 419:195-8.

Bosch TM, Deenen M, Pruntel R et al. Screening for polymorphisms in the PXR gene in a Dutch population. Eur J Clin Pharmacol 2006; 62:395-9.

Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther 2006; 10:175-85.

Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006; 45:253-85.

Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26:312-8.

Bosia M, Anselmetti S, Pirovano A et al. HTTLPR functional polymorphism in schizophrenia: executive functions vs. sustained attention dissociation. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:81-5.

Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 1995; 333:1171-5.

Bosma PJ, Chowdhury JR, Huang TJ et al. Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I. FASEB J 1992; 6:2859-63.

Bosma PJ, Chowdhury NR, Goldhoorn BG et al. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 1992; 15:941-7.

Bosma PJ, Goldhoorn B, Oude Elferink RP, Sinaasappel M, Oostra BA, Jansen PL. A mutation in bilirubin uridine 5’-diphosphate-glucuronosyltransferase isoform 1 causing Crigler-Najjar syndrome type II. Gastroenterology 1993; 105:288-93.

Bosron WF, Magnes LJ, Li TK. Human liver alcohol dehydrogenase: ADH(Indianapolis) results from genetic polymorphism at the ADH-2 gene locus. Biochem Genet 1983; 21:735-44.

Bossé Y, Lemire M, Poon AH et al. Asthma and genes encoding components of the vitamin D pathway. Respir Res 2009; 10:98.

Bossé Y, Vohl MC, Dumont M et al. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clin Genet 2002; 62:45-52.

Bosso JA, Liu Q, Evans WE, Relling MV. CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosis. Pharmacotherapy 1996; 16:749-53.

Bot I, Jukema JW, Lankhuizen IM, van Berkel TJ, Biessen EA. Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Atherosclerosis 2011; 214:295-300.

Bothe H, Gassmann K, Götz C, Fritsche E, Abel J, Haarmann-Stemmann T. Epigallocatechin-3-gallate does not affect the activity of enzymes involved in metabolic activation and cellular excretion of benzo[a]pyrene in human colon carcinoma cells. Toxicol Lett 2011; 203:258-64.

Bothe H, Götz C, Stobbe-Maicherski N, Fritsche E, Abel J, Haarmann-Stemmann T. Luteolin enhances the bioavailability of benzo(a)pyrene in human colon carcinoma cells. Arch Biochem Biophys 2010; 498:111-8.

Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993; 43:120-6.

Böttiger Y. Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. Eur J Clin Pharmacol 2006; 62:621-5.

Böttiger Y, Säwe J, Brattström C et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 2001; 69:32-40.

Böttiger Y, Tybring G, Götharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62:384-91.

Bottini N, de Luca D, Saccucci P et al. Autism: evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics 2001; 3:111-3.

Bottke D, Koychev D, Busse A et al. Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. Radiat Res 2008; 170:41-8.

Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 2011; 72:442-50.

Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97:27-31.

Bottova I, Sauder U, Olivieri V, Hehl AB, Sonda S. The P-glycoprotein inhibitor GF120918 modulates Ca2+-dependent processes and lipid metabolism in Toxoplasma gondii. PLoS One 2010. doi:10. 1371/journal. pone. 0010062.

Bouamar R, Hesselink DA, van Schaik RH et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit 2011; 33:178-84.

Bouchard L, Faucher G, Tchernof A et al. Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals. Acta Diabetol 2009; 46:13-21.

Bouchet BP, Galmarini CM. Cabazitaxel, a new taxane with favorable properties. Drugs Today 2010; 46:735-42.

Boudinot E, Bernard V, Camp S et al. Influence of differential expression of acetylcholinesterase in brain and muscle on respiration. Respir Physiol Neurobiol 2009; 165:40-8.

Bouguerne B, Belkheiri N, Bedos-Belval F et al. Antiatherogenic effect of bisvanillyl-hydralazone, a new hydralazine derivative with antioxidant, carbonyl scavenger, and antiapoptotic properties. Antioxid Redox Signal 2011; 14:2093-106.

Bouhali K, Dipietromaria A, Fontaine A et al. Allelic reduction of Dlx5 and Dlx6 results in early follicular depletion: a new mouse model of primary ovarian insufficiency. Hum Mol Genet 2011; 20:2642-50.

Boulange-Lecomte C, Geraudie P, Forget-Leray J, Gerbron M, Minier C. Ligula intestinalis infection is associated with alterations of both brain and gonad aromatase expression in roach (Rutilus rutilus). J Helminthol 2011; 85:339-44.

Boulton DW, Arnaud P, DeVane CL. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 2001; 70:48-57.

Boulton DW, deVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71:163-9.

Boumpas DT, Anastassiou ED, Older SA, Tsokos GC, Nelson DL, Balow JE. Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J Clin Invest 1991; 87:1739-47.

Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A. Prion protein protects human neurons against Bax-mediated apoptosis. J Biol Chem 2001; 276:39145-9.

Bouquié R, Deslandes G, Renaud C, Dailly E, Haloun A, Jolliet P. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol 2011; 17:28-30.

Bouraïma-Lelong H, Vanneste M, Delalande C, Zanatta L, Wolczynski S, Carreau S. Aromatase gene expression in immature rat Sertoli cells: age-related changes in the FSH signalling pathway. Reprod Fertil Dev 2010; 22:508-15.

Bourcier K, Hyland R, Kempshall S et al. Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos 2010; 38:923-9.

Bourdeaut F, Hérault A, Gentien D et al. Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. J Med Genet 2010; 47:859-62.

Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, Geary TG. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am J Trop Med Hyg 2010; 83:28-32.

Bourguinat C, Keller K, Blagburn B, Schenker R, Geary TG, Prichard RK. Correlation between loss of efficacy of macrocyclic lactone heartworm anthelmintics and P-glycoprotein genotype. Vet Parasitol 2011; 176:374-81.

Bourguinat C, Keller K, Prichard RK, Geary TG. Genetic polymorphism in Dirofilaria immitis. Vet Parasitol 2011; 176:368-73.

Bourkiza R, Joyce S, Patel H et al. Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1-a case report. Ophthalmic Genet 2010; 31:73-6.

Bournique B, Lambert N, Boukaiba R, Martinet M. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide). Br J Clin Pharmacol 2001; 52:53-63.

Bournique B, Petry M, Gousset G. Usefulness of statistic experimental designs in enzymology: example with recombinant hCYP3A4 and 1A2. Anal Biochem 1999; 276:18-26.

Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009; 50:898-903.

Bourquard N, Ng CJ, Reddy ST. Impaired hepatic insulin signalling in PON2-deficient mice: a novel role for the PON2/apoE axis on the macrophage inflammatory response. Biochem J 2011; 436:91-100.

Bourrié M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996; 277:321-32.

Bourrié M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27:288-96.

Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother 2009; 53:896-902.

Boutros PC, Yao CQ, Watson JD et al. Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicol Appl Pharmacol 2011; 251:119-29.

Bouvard B, Hoppé E, Soulié P et al. High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann Oncol 2011. doi:10. 1093/annonc/mdr356.

Bouwman AC, Bovenhuis H, Visker MH, van Arendonk JA. Genome-wide association of milk fatty acids in Dutch dairy cattle. BMC Genet 2011; 12:43.

Bowen WP, Carey JE, Miah A et al. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 2000; 28:781-8.

Bowers DJ, Calvano JE, Alvarez SM et al. Polymorphisms of heat shock protein-70 (HSPA1B and HSPA1L loci) do not influence infection or outcome risk in critically ill surgical patients. Shock 2006; 25:117-22.

Bowers JM, Waddell J, McCarthy MM. A developmental sex difference in hippocampal neurogenesis is mediated by endogenous oestradiol. Biol Sex Differ 2010; 1:8.

Boyd RA, Stern RH, Stewart BH et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40:91-8.

Boyer SH, Sun Z, Jiang H et al. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem 2006; 49:7711-20.

Boyle J, Kill IR, Parris CN. Heterogeneity of dimer excision in young and senescent human dermal fibroblasts. Aging Cell 2005; 4:247-55.

Bozdag G, Alp A, Saribas Z, Tuncer S, Aksu T, Gurgan T. CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis. Reprod Biomed Online 2010; 20:286-90.

Bozina N, Bradamante V, Lovrić M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 2009; 60:217-42.

Bozina N, Jovanović N, Lovrić M, Medved V. Clinical significance of a CYP2D6 poor metabolizer-a patient with schizophrenia on risperidone treatment. Ther Drug Monit 2008; 30:748-51.

Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008; 42:89-97.

Bozkurt O, de Boer A, Grobbee DE et al. Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens 2009; 22:545-51.

Bozkurt O, de Boer A, Grobbee DE, Heerdink ER, Burger H, Klungel OH. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol Diagn Ther 2007; 11:291-302.

Bozkurt O, Verschuren WM, van Wieren-de Wijer BM et al. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. J Hum Hypertens 2008; 22:774-80.

Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F. Chemoprevention for breast cancer. Cancer Treat Rev 2011. doi:10. 1016/j. ctrv. 2011. 07. 005.

Bozzuto G, Colone M, Toccacieli L, Stringaro A, Molinari A. Tea tree oil might combat melanoma. Planta Med 2011; 77:54-6.

Braam W, van Geijlswijk I, Keijzer H, Smits MG, Didden R, Curfs LM. Loss of response to melatonin treatment is associated with slow melatonin metabolism. J Intellect Disabil Res 2010; 54:547-55.

Bracale R, Pasanisi F, Labruna G et al. Metabolic syndrome and ADRB3 gene polymorphism in severely obese patients from South Italy. Eur J Clin Nutr 2007; 61:1213-9.

Brackbill ML, Kidd RS, Abdoo AD, Warner JG Jr, Harralson AF. Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart Vessels 2009; 24:73-8.

Brackenbury WJ, Davis TH, Chen C et al. Voltage-gated Na+ channel beta1 subunit-mediated neurite outgrowth requires Fyn kinase and contributes to postnatal CNS development in vivo. J Neurosci 2008; 28:3246-56.

Brackett CC, Bloch JD. Phenytoin as a possible cause of acetaminophen hepatotoxicity: case report and review of the literature. Pharmacotherapy 2000; 20:229-33.

Bracht K, Liebeke M, Ritter CA, Grünert R, Bednarski PJ. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. Anticancer Drugs 2007; 18:389-404.

Brachtendorf L, Jetter A, Beckurts KT, Hölscher AH, Fuhr U. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 2002; 90:144-9.

Bradberry SM, Cage SA, Proudfoot AT, Vale JA. Poisoning due to pyrethroids. Toxicol Rev 2005; 24:93-106.

Bradbury PA, Kulke MH, Heist RS et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 2009; 19:613-25.

Bradbury PA, Zhai R, Ma C et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009; 15:4680-5.

Bradford J, Shin JY, Roberts M, Wang CE, Li X-J, Li SH. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci USA 2009; 106:22480-5.

Bradford J, Shin JY, Roberts M, Wang CE, Li X-J, Li SH. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 2010; 285:10653-61.

Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3:229-43.

Braeuning A, Köhle C, Buchmann A, Schwarz M. Coordinate regulation of cytochrome P450 1A1 expression in mouse liver by the aryl hydrocarbon receptor and the {beta}-catenin pathway. Toxicol Sci 2011; 122:16-25.

Brainard DM, Kassahun K, Wenning LA et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol 2011; 51:943-50.

Brakensiek K, Frye-Boukhriss H, Mälzer M et al. Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia. Clin Genet 2008; 74:171-7.

Bram EE, Stark M, Raz S, Assaraf YG. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 2009; 11:1359-70.

Brancati F, Valente EM, Castori M et al. Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystonia. J Neurol Neurosurg Psychiatry 2003; 74:665-6.

Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 2000; 68:401-11.

Branch RA, Chern HD, Adedoyin A et al. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995; 5 Spec No:S97-102.

Brand E, Chatelain N, Paillard F et al. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur J Hum Genet 2002; 10:715-23.

Brand W, Boersma MG, Bik H et al. Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab Dispos 2010; 38:617-25.

Brand W, Padilla B, van Bladeren PJ, Williamson G, Rietjens IM. The effect of co-administered flavonoids on the metabolism of hesperetin and the disposition of its metabolites in Caco-2 cell monolayers. Mol Nutr Food Res 2010; 54:851-60.

Brand W, van der Wel PA, Rein MJ et al. Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab Dispos 2008; 36:1794-802.

Brandel JP, Preece M, Brown P et al. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet 2003; 326:128-30.

Brandes LJ. N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer. Hum Exp Toxicol 2008; 27:143-7.

Brandes LJ, Queen GM, LaBella FS. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol 2000; 45:298-304.

Brandhorst G, Tenderich G, Zittermann A et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008; 30:113-6.

Brandin H, Myrberg O, Rundlöf T, Arvidsson AK, Brenning G. Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy. Eur J Clin Pharmacol 2007; 63:565-70.

Brandin H, Viitanen E, Myrberg O, Arvidsson AK. Effects of herbal medicinal products and food supplements on induction of CYP1A2, CYP3A4 and MDR1 in the human colon carcinoma cell line LS180. Phytother Res 2007; 21:239-44.

Brandon EF, Sparidans RW, Guijt KJ et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs 2006; 24:3-14.

Brandon EF, Sparidans RW, Meijerman I, Manzanares I, Beijnen JH, Schellens JH. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. Invest New Drugs 2004; 22:241-51.

Brandon EF, Sparidans RW, van Ooijen RD et al. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs 2007; 25:9-19.

Brandon-Warner E, Sugg JA, Schrum LW, McKillop IH. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett 2010; 291:120-9.

Brandstätter A, Lamina C, Kiechl S et al. Sex and age interaction with genetic association of atherogenic uric acid concentrations. Atherosclerosis 2010; 210:474-8.

Brandt JT, Close SL, Iturria SJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5:2429-36.

Brandt S. TERT over-expression affects the growth of myocardial tissue derived from mouse embryonic stem cells. Differentiation 2010; 79:1-8.

Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009; 114:5426-35.

Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99:3472-5.

Brannan MD, Reidenberg P, Radwanski E et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58:269-78.

Brant SR, Panhuysen CIM, Nicolae D et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003; 73:282-92.

Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114:2168-73.

Braoudaki M, Karpusas M, Katsibardi K et al. Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. Med Oncol 2009; 26:460-2.

Brasch-Andersen C, Møller MU, Christiansen L et al. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). Eur J Clin Pharmacol 2011; 67:1131-7.

Brasier AR, Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 1996; 27:465-75.

Bratton SM, Mosher CM, Khallouki F et al. Analysis of R- and S-Hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther 2011. doi:10. 1124/jpet. 111. 184721.

Brauch H, Jordan VC. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the ‘personalised’ approach? Eur J Cancer 2009; 45:2274-83.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009; 55:1770-82.

Braun A, Kammerer S, Bohme E, Muller B, Roscher AA. Identification of polymorphic sites of the human bradykinin B (2) receptor gene. Biochem Biophys Res Commun 1995; 211:234-40.

Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26:2690-8.

Braun MS, Richman SD, Thompson L et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27:5519-28.

Brave M, Goodman V, Kaminskas E et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008; 14:352-9.

Bravo CF, Curtis LR, Myers MS et al. Biomarker responses and disease susceptibility in juvenile rainbow trout Oncorhynchus mykiss fed a high molecular weight PAH mixture. Environ Toxicol Chem 2011; 30:704-14.

Bray J, Sludden J, Griffin MJ et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102:1003-9.

Bray NJ, Preece A, Williams NM et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet 2005; 14:1947-54.

Bray PF, Cannon CP, Goldschmidt-Clermont P et al. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88:347-52.

Brazier MW, Volitakis I, Kvasnicka M et al. Manganese chelation therapy extends survival in a mouse model of M1000 prion disease. J Neurochem 2010; 114:440-51.

Breast and Prostate Cancer Cohort Consortium; Cox DG, Bretsky P et al. Haplotypes of the estrogen receptor beta gene and breast cancer risk. Int J Cancer 2008; 122:387-92.

Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349:1505-10.

Brechbuhl HM, Gould N, Kachadourian R, Riekhof WR, Voelker DR, Day BJ. Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J Biol Chem 2010; 285:16582-7.

Brecht WJ, Harris FM, Chang S et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 2004; 24:2527-34.

Bredberg E, Andersson TB, Frison L et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003; 42:765-77.

Bredschneider M, Klein K, Mürdter TE et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther 2002; 71:479-87.

Breedveld P, Pluim D, Cipriani G et al. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 2007; 71:240-9.

Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brøsen K, Friedberg T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 2002; 40:609-16.

Breitling LP, Dahmen N, Mittelstraß K et al. Association of nicotinic acetylcholine receptor subunit alpha4 polymorphisms with nicotine dependence in 5500 Germans. Pharmacogenomics J 2009; 19:657-9.

Bremer T, Diamond C, McKinney R et al. The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol Diagn Ther 2007; 11:161-70.

Brennan B, Chiu Y, Berthelon L, Kolis S, Davies B. Effect of age and gender on the pharmacokinetics of R667, a novel agent for the treatment of emphysema, in healthy volunteers. J Pharm Pharm Sci 2007; 10:9-16.

Brennan BJ, Brown AB, Kolis SJ, Rutman O, Gooden C, Davies BE. Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men. J Clin Pharmacol 2006; 46:222-8.

Brennan P, Lewis S, Hashibe M et al. Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review. Am J Epidemiol 2004; 159:1-16.

Brennan RM, Burrows SR. A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis. Blood 2008; 112:2589-90.

Brenner SS, Herrlinger C, Dilger K et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42:283-92.

Brent D, Melhem N, Ferrell R et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2010; 167:190-7.

Bressler R. Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 2006; 61:12-8.

Breuer MA, Schmidt B, Schuphan I. Utility of Nicotiana tabacum cell suspension cultures expressing human CYP1A1, CYP1A2 and CYP3A4 to study the oxidative metabolism of the herbicide 14C-fluometuron. Drug Metab Lett 2009; 3:18-27.

Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev 2004; 36:723-46.

Bridges CC, Joshee L, Zalups RK. MRP2 and the DMPS- and DMSA-mediated elimination of mercury in TR(-) and control rats exposed to thiol S-conjugates of inorganic mercury. Toxicol Sci 2008; 105:211-20.

Bridges CC, Joshee L, Zalups RK. MRP2 and the handling of mercuric ions in rats exposed acutely to inorganic and organic species of mercury. Toxicol Appl Pharmacol 2011; 251:50-8.

Bridges SL Jr, Kelley JM, Hughes LB. The HLA-DRB1 shared epitope in Caucasians with rheumatoid arthritis: a lesson learned from tic-tac-toe. Arthritis Rheum 2008; 58:1211-5.

Briest S, Stearns V. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol 2009; 7:185-92.

Brigelius-Flohé R. Vitamin E and drug metabolism. Biochem Biophys Res Commun 2003; 305:737-40.

Brigelius-Flohé R. Induction of drug metabolizing enzymes by vitamin E. J Plant Physiol 2005; 162:797-802.

Brignac-Huber L, Reed JR, Backes WL. Organization of NADPH-cytochrome P450 reductase and CYP1A2 in the endoplasmic reticulum-microdomain localization affects monooxygenase function. Mol Pharmacol 2011; 79:549-57.

Brill S, Zimmermann C, Berger K, Drewe J, Gutmann H. In vitro interactions with repeated grapefruit juice administration-to peel or not to peel? Planta Med 2009; 75:332-5.

Brimer C, Dalton JT, Zhu Z et al. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharm Res 2000; 17:803-10.

Brinkman A, de Jong D, Tuinman S, Azaouagh N, van Agthoven T, Dorssers LC. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells. Breast Cancer Res Treat 2010; 120:401-8.

Brinks H, Koch WJ. Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure. Drug Discov Today Dis Mech 2010; 7:129-34.

Brionne TC, Tesseur I, Masliah E, Wyss-Coray T. Loss of TGF-beta-1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 2003; 40:1133-45.

Brisson D, Ledoux K, Bossé Y et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 2002; 12:313-20.

Bristow MR, Murphy GA, Krause-Steinrauf H et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010; 3:21-8.

Brito DD, Fernandes AP, Gomes KB et al. Apolipoprotein A5-1131T>C polymorphism, but not APOE genotypes, increases susceptibility for dyslipidemia in children and adolescents. Mol Biol Rep 2011; 38:4381-8.

Britten AC, Mijovic CH, Barnett AH, Kelly MA. Differential expression of HLA-DQ alleles in peripheral blood mononuclear cells: alleles associated with susceptibility to and protection from autoimmune type 1 diabetes. Int J Immunogenet 2009; 36:47-57.

Britzi M, Bialer M, Arcavi L, Shachbari A, Kapitulnik T, Soback S. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Ther Drug Monit 2000; 22:510-6.

Broccatelli F, Carosati E, Neri A et al. A Novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 2011; 54:1740-51.

Brocic M, Supic G, Zeljic K et al. Genetic polymorphisms of ADH1C and CYP2E1 and risk of oral squamous cell carcinoma. Otolaryngol Head Neck Surg 2011; 145:586-93.

Brock MV, Hooker CM, Ota-Machida E et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358:1118-28.

Brock O, Douhard Q, Baum MJ, Bakker J. Reduced prepubertal expression of progesterone receptor in the hypothalamus of female aromatase knockout mice. Endocrinology 2010; 151:1814-21.

Brockman R, Bunick D, Mahoney MM. Estradiol deficiency during development modulates the expression of circadian and daily rhythms in male and female aromatase knockout mice. Horm Behav 2011; 60:439-47.

Brockmöller J, Kirchheiner J, Schmider J et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72:438-52.

Brockmöller J, Meineke I, Kirchheiner J. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultrarapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther 2007; 81:699-707.

Brodde OE. The functional importance of beta 1 and beta 2 adrenoceptors in the human heart. Am J Cardiol 1988; 62:24-9.

Brodde OE. Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 2008; 117:1-29.

Brodde OE. Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam Clin Pharmacol 2008; 22:107-25.

Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung 2003; 53:814-22.

Broderick J, Lu M, Jackson C et al. Apolipoprotein E, phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol 2001; 49:736-44.

Brody LC, Conley M, Cox C et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet 2002; 71:1207-15.

Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008; 3:560-70.

Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10:545-58.

Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol 1990; 39:1045-53.

Broly F, Marez D, Lo Guidice JM et al. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum Genet 1995; 96:601-3.

Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993; 3:123-30.

Bronner IM, Hoogendijk JE, de Visser M et al. Association of the leukocyte immunoglobulin G (Fcgamma) receptor IIIa-158V/F polymorphism with inflammatory myopathies in Dutch patients. Tissue Antigens 2009; 73:586-9.

Bronson NW, Hamilton JS, Han M et al. LOXL null mice demonstrate selective dentate structural changes but maintain dentate granule cell and CA1 pyramidal cell potentiation in the hippocampus. Neurosci Lett 2005; 390:118-22.

Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 1992; 2:208-21.

Brooks TA, Kennedy DR, Gruol DJ, Ojima I, Baer MR, Bernacki RJ. Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Res 2004; 24:409-15.

Brooks-Wilson A, Marcil M, Clee SM et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22:336-45.

Brophy DF, Israel DS, Pastor A et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob Agents Chemother 2000; 44:978-84.

Brophy JM, Babapulle MN, Costa V, Rinfret S. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. Am Heart J 2006; 152:263-9.

Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18:393-6.

Brøsen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol 1998; 13 Suppl 5:45-7.

Brøsen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004; 59:5-12.

Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44:349-55.

Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11:275-83.

Brøsen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991; 49:609-17.

Brouillette C, Bossé Y, Pérusse L, Gaudet D, Vohl MC. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J Hum Genet 2004; 49:424-32.

Brousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 2007; 150:623-6.

Brousseau ME, Goldkamp AL, Collins D et al. Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial. J Lipid Res 2004; 45:1885-91.

Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. New Eng J Med 2004; 350:1505-15.

Broussolle E, Thobois S. Genetics and environmental factors of Parkinson disease. Rev Neurol 2002; 158:11-23.

Brouwer KC, Lal RB, Mirel LB et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 2004; 18:1187-94.

Brouwers EE, Söhne M, Kuipers S et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 2009; 29:59-63.

Brouwers N, van Cauwenberghe C, Engelborghs S et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 2011. doi:10. 1038/mp. 2011. 24.

Brown AR, Bickley LK, Le Page G et al. Are toxicological responses in laboratory (inbred) zebrafish representative of those in outbred (wild) populations? – A case study with an endocrine disrupting chemical. Environ Sci Technol 2011; 45:4166-72.

Brown B, Huang MH, Karlamangla A, Seeman T, Kado D. Do the effects of APOE-ε4 on cognitive function and decline depend upon vitamin status? MacArthur Studies of Successful Aging. J Nutr Health Aging 2011; 15:196-201.

Brown CS, Farmer RG, Soberman JE, Eichner SF. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet 2004; 43:33-56.

Brown HS, Galetin A, Hallifax D, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006; 45:1035-50.

Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005; 60:508-18.

Brown J, Lantos PL, Roques P, Fidani L, Rossor MN. Familial dementia with swollen achromatic neurons and corticobasal inclusion bodies: a clinical and pathological study. J Neurol Sci 1996; 135:21-30.

Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 2010; 123:591-6.

Brown KM, Bujac SR, Mann ET, Campbell DA, Stubbins MJ, Blundell JE. Further evidence of association of OPRD1 & HTR1D polymorphisms with susceptibility to anorexia nervosa. Biol Psychiatry 2007; 61:367-73.

Brown MA, Edwards S, Hoyle E et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Molec Genet 2000; 9:1563-6.

Brown MD, Sun F, Wallace DC. Clustering of Caucasian Leber hereditary optic neuropathy patients containing the 11778 or 14484 mutations on an mtDNA lineage. Am J Hum Genet 1997; 60:381-7.

Brown MD, Voljavec AS, Lott MT, Torroni A, Yang CC, Wallace DC. Mitochondrial DNA complex I and III mutations associated with Leber’s hereditary optic neuropathy. Genetics 1992; 130:163-73.

Brown MD, Wallace DC. Molecular basis of mitochondrial DNA disease. J Bioenerg Biomembr 1994; 26:273-89.

Brown SD. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia. Drug Saf 2008; 31:561-75.

Browning SL, Tarekegn A, Bekele E, Bradman N, Thomas MG. CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics 2010; 20:647-64.

Broyl A, Corthals SL, Jongen JL et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010; 11:1057-65.

Brozzetti A, Marzotti S, Tortoioli C et al. Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. Eur J Endocrinol 2010; 162:361-9.

Bruandet A, Richard F, Tzourio C et al. Haplotypes across ACE and the risk of Alzheimer’s disease: the three-city study. J Alzheimers Dis 2008; 13:333-9.

Bruck H, Leineweber K, Park J et al. Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo. Clin Pharmacol Ther 2005; 78:232-8.

Bruchova H, Vasikova A, Merkerova M et al. Effect of maternal tobacco smoke exposure on the placental transcriptome. Placenta 2010; 31:186-91.

Brüggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med 2006; 34:2201-6.

Brugts JJ, de Maat MP, Boersma E et al. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2009; 23:171-81.

Brugts JJ, Isaacs A, Boersma E et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J 2010; 31:1854-64.

Brugts JJ, Yetgin T, Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338:2376.

Bruin GJ, Faller T, Wiegand H et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 2008; 36:2523-38.

Brumme ZL, Chan KJ, Dong W et al. CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. AIDS 2001; 15:2259-66.

Brumme ZL, Henrick BM, Brumme CJ, Hogg RS, Montaner JS, Harrigan PR. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. Antivir Ther 2005; 10:849-53.

Brunden KR, Yao Y, Potuzak JS et al. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer’s disease and related tauopathies. Pharmacol Res 2011; 63:341-51.

Brunham LR, Kruit JK, Iqbal J et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006; 116:1052-62.

Brunham LR, Kruit JK, Pape TD et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13:340-7.

Brunham LR, Lansberg PJ, Zhang L et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2011. doi:10. 1038/tpj. 2010. 92.

Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993; 262:578-80.

Bruns S, Stark Y, Röker S et al. Collagen biomaterial doped with colominic acid for cell culture applications with regard to peripheral nerve repair. J Biotechnol 2007; 131:335-45.

Brüss M, Bönisch H, Bühlen M, Nöthen MM, Propping P, Göthert M. Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. Pharmacogenetics 1999; 9:95-102.

Bruyère A, Declèves X, Bouzom F et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm 2010; 7:1596-607.

Bruyne SD, Wyffels L, Moerman L et al. Radiosynthesis and in vivo evaluation of [(11)C]MC80 for P-glycoprotein imaging. Bioorg Med Chem 2010; 18:6489-95.

Bryan A, Watters C, Koenig L et al. Human transcriptome analysis reveals a potential role for active transport in the metabolism of Pseudomonas aeruginosa autoinducers. Microbes Infect 2010; 12:1042-50.

Bryan J, Muñoz A, Zhang X et al. ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch 2007; 453:703-18.

Bryant CD, Graham ME, Distler MG et al. A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. Psychopharmacology 2009; 203:703-11.

Brynedal B, Duvefelt K, Jonasdottir G et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007. doi:10. 1371/journal. pone. 0000664.

Brynne N, Böttiger Y, Hallén B, Bertilsson L. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Br J Clin Pharmacol 1999; 47:145-50.

Brynne N, Forslund C, Hallén B, Gustafsson LL, Bertilsson L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999; 48:564-72.

Brynne N, Svanström C, Aberg-Wistedt A, Hallén B, Bertilsson L. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol 1999; 48:553-63.

Bryson GL, Wyand A, Wozny D, Rees L, Taljaard M, Nathan H. A prospective cohort study evaluating associations among delirium, postoperative cognitive dysfunction, and apolipoprotein E genotype following open aortic repair. Can J Anaesth 2011; 58:246-55.

Bu FX, Armas L, Lappe J et al. Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet 2010; 128:549-56.

Bu HZ. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. Curr Drug Metab 2006; 7:231-49.

Bu HZ, Knuth K, Magis L, Teitelbaum P. High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. Rapid Commun Mass Spectrom 2000; 4:1943-8.

Bu HZ, Pool WF, Wu EY, Raber SR, Amantea MA, Shetty BV. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos 2004; 32:689-98.

Bu HZ, Zhao P, Kang P, Pool WF, Wu EY, Shetty BV. Evaluation of capravirine as a CYP3A probe substrate: in vitro and in vivo metabolism of capravirine in rats and dogs. Drug Metab Dispos 2007; 35:1593-602.

Bu HZ, Zhao P, Kang P, Pool WF, Wu EY. Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos 2006; 34:1798-802.

Bu X, Xing G, Yan M. Audiological and molecular findings in a large family with maternally inherited sensorineural hearing loss. J Audiol Med 2000; 9:61-9.

Bucaretchi F, de Capitani EM, Mello SM et al. Serotonin syndrome following sibutramine poisoning in a child, with sequential quantification of sibutramine and its primary and secondary amine metabolites in plasma. Clin Toxicol 2009; 47:598-601.

Buck D, Diefenbach K, Penzel T, Malzahn U, Roots I, Fietze I. Genetic polymorphisms in endothelin-receptor-subtype-a-gene as susceptibility factor for obstructive sleep apnea syndrome. Sleep Med 2010; 11:213-7.

Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep 2008; 60:623-31.

Buch S, Schafmayer C, Völzke H et al. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology 2010; 139:1942-51.

Buch T, Uthoff-Hachenberg C, Waisman A. Protection from autoimmune brain inflammation in mice lacking IFN-regulatory factor-1 is associated with Th2-type cytokines. Int Immunol 2003; 15:855-9.

Buchanan FF, Myles PS, Cicuttini F. Patient sex and its influence on general anaesthesia. Anaesth Intensive Care 2009; 37:207-18.

Buchard A, Linnet K, Johansen SS, Munkholm J, Fregerslev M, Morling N. Postmortem blood concentrations of R-and S-enantiomers of methadone and EDDP in drug users: influence of co-medication and P-glycoprotein genotype. J Forensic Sci 2010; 55:457-63.

Buchkowsky SS, Partovi N, Ensom MH. Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit 2005; 27:322-33.

Buda G, Ricci D, Huang CC et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2010; 89:1133-40.

Budinsky RA, LeCluyse EL, Ferguson SS, Rowlands JC, Simon T. Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran. Toxicol Sci 2010; 118:224-35.

Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7:273-82.

Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, Foster BC. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 2007; 85:966-78.

Buehler BA, Delimont D, van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990; 322:1567-72.

Buervenich S, Carmine A, Galter D et al. A rare truncating mutation in ADH1C (G78stop) shows significant association with Parkinson disease in a large international sample. Arch Neurol 2005; 62:74-8.

Buetow K, Shiang R, Yang P et al. A detailed multipoint map of human chromosome 4 provides evidence for linkage heterogeneity and position-specific recombination-specific recombination rates. Am J Hum Genet 1991; 48:911-25.

Buhler MM, Craig M, Donaghue KC et al. CCR5 genotyping in an Australian and New Zealand type 1 diabetes cohort. Autoimmunity 2002; 35:457-61.

Bui P, Imaizumi S, Beedanagari SR, Reddy ST, Hankinson O. Human CYP2S1 metabolizes cyclooxygenase- and lipoxygenase-derived eicosanoids. Drug Metab Dispos 2011; 39:180-90.

Bui PH, Hsu EL, Hankinson O. Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyrene-7,8-dihydrodiol. Mol Pharmacol 2009; 76:1044-52.

Bui PH, Quesada A, Handforth A, Hankinson O. The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. Drug Metab Dispos 2008; 36:1291-9.

Buisson M, Anczukow O, Zetoune AB, Ware MD, Mazoyer S. The 185delAG mutation (c. 68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat 2006; 27:1024-9.

Bulchandani DG, Nachnani JS, Nookala A et al. Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis. Eur J Gastroenterol Hepatol 2010; 22:1245-52.

Bulotta A, Ludovico O, Coco A et al. The common -866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy. J Clin Endocrinol Metab 2005; 90:1176-80.

Bullido MJ, Artiga MJ, Recuero M et al. A polymorphism in the regulatory region of APOE association with risk for Alzheimer’s dementia. Nat Genet 1998; 18:69-71.

Bullock P, Pearce R, Draper A et al. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab Dispos 1995; 23:736-48.

Bunce C, Hitchings RA, Bhattacharya SS, Lehmann OJ. Single-nucleotide polymorphisms and glaucoma severity. Am J Hum Genet 2003; 72:1593-4.

Bunce D, Anstey KJ, Burns R, Christensen H, Easteal S. Does possession of apolipoprotein E ε4 benefit cognitive function in healthy young adults? Neuropsychologia 2011; 49:1693-7.

Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010; 88:383-9.

Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 2011; 16:142-4.

Buoni S, Orrico A, Galli L et al. SCN1A (2528delG) novel truncating mutation with benign outcome of severe myoclonic epilepsy of infancy. Neurology 2006; 66:606-7.

Buqué X, Martínez MJ, Cano A et al. A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. J Lipid Res 2010; 51:500-13.

Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A. Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant 2006; 21:979-83.

Buraczyńska M, Pijanowski Z, Spasiewicz D et al. Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease. Kardiol Pol 2003; 58:1-9.

Buratti FM, de Angelis G, Ricceri L, Venerosi A, Calamandrei G, Testai E. Foetal and neonatal exposure to chlorpyrifos: biochemical and metabolic alterations in the mouse liver at different developmental stages. Toxicology 2011; 280:98-108.

Buratti FM, Leoni C, Testai E. Foetal and adult human CYP3A isoforms in the bioactivation of organophosphorothionate insecticides. Toxicol Lett 2006; 167:245-55.

Buratti FM, Testai E. Evidences for CYP3A4 autoactivation in the desulfuration of dimethoate by the human liver. Toxicology 2007; 241:33-46.

Buratti FM, Volpe MT, Meneguz A, Vittozzi L, Testai E. CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicol Appl Pharmacol 2003; 186:143-54.

Burckart GJ, Amur S. Update on the clinical pharmacogenomics of organ transplantation. Pharmacogenomics 2010; 11:227-36.

Burdette-Radoux S, Tozer RG, Lohmann RC et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004; 22:315-22.

Burdick KE, DeRosse P, Kane JM, Lencz T, Malhotra AK. Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry 2010; 167:436-43.

Burdick KE, Goldberg TE, Funke B et al. DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr Res 2007; 89:169-72.

Burdon KP, Hewitt AW, Mackey DA, Mitchell P, Craig JE. Tag SNPs detect association of the CYP1B1 gene with primary open angle glaucoma. Mol Vis 2010; 16:2286-93.

Burdon KP, Langefeld CD, Wagenknecht LE et al. Association analysis of genes in the renin-angiotensin system with subclinical cardiovascular disease in families with Type 2 diabetes mellitus: the Diabetes Heart Study. Diabet Med 2006; 23:228-34.

Burger H, den Bakker MA, Kros JM et al. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005; 4:1270-4.

Burger H, Foekens JA, Look MP et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003; 9:827-36.

Burgess B, Naus K, Chan J et al. Overexpression of human ABCG1 does not affect atherosclerosis in fat-fed ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2008; 28:1731-7.

Burgess BL, Parkinson PF, Racke MM et al. ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J Lipid Res 2008; 49:1254-67.

Burgess JK, Lindeman R, Chesterman CN, Chong BH. Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 1995; 91:761-6.

Burhenne J, Matthée AK, Pasáková I et al. No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother 2010; 54:4185-91.

Burk O, Arnold KA, Nussler AK et al. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 2005; 67:1954-65.

Burk O, Brenner SS, Hofmann U et al. The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin. Clin Pharmacol Ther 2010; 88:685-94.

Burk O, Koch I, Raucy J et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 2004; 279:38379-85.

Burk O, Tegude H, Koch I et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 2002; 277:24280-8.

Burke JR, Enghild JJ, Martin ME et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996; 2:347-50.

Burke KT, Horn PS, Tso P, Heubi JE, Woollett LA. Hepatic bile acid metabolism in the neonatal hamster: expansion of the bile acid pool parallels increased Cyp7a1 expression levels. Am J Physiol Gastrointest Liver Physiol 2009; 297:144-51.

Burmester JK, Berg RL, Glurich I, Yale SH, Schmelzer JR, Caldwell MD. Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses. Clin Med Res 2011. doi:10. 3121/cmr. 2011. 951.

Burnell JC, Carr LG, Dwulet FE, Edenberg HJ, Li TK, Bosron WF. The human beta(3) alcohol dehydrogenase subunit differs from beta-1 by a cys for Arg-369 substitution which decreases NAD(H) binding. Biochem Biophys Res Commun 1987; 146:1227-33.

Burns JC, Shimizu C, Gonzalez E et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 2005; 192:344-9.

Buroker NE, Ning XH, Zhou ZN et al. Genetic associations with mountain sickness in Han and Tibetan residents at the Qinghai-Tibetan Plateau. Clin Chim Acta 2010; 411:1466-73.

Burris RL, Xie CH, Thampi P, Wu X, Melnyk SB, Nagarajan S. Dietary rice protein isolate attenuates atherosclerosis in apoE-deficient mice by upregulating antioxidant enzymes. Atherosclerosis 2010; 212:107-15.

Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John’s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000; 68:605-12.

Burstein AH, Reiss WG, Kantor E, Anderson GD. Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios. Pharmacotherapy 1998; 18:1271-6.

Burt HJ, Galetin A, Houston JB. IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. Xenobiotica 2010; 40:331-43.

Burton JR, Burton I, Pearson GJ. Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient. Ann Pharmacother 2007; 41:133-7.

Burul-Bozkurt N, Pekiner C, Kelicen P. Diabetes alters aromatase enzyme levels in gonadal tissues of rats. Naunyn Schmiedebergs Arch Pharmacol 2010; 382:33-41.

Busby WF Jr, Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 1999; 27:246-9.

Busby WF Jr, Penman BW, Crespi CL. Human cell mutagenicity of mono- and dinitropyrenes in metabolically competent MCL-5 cells. Mutat Res 1994; 322:233-42.

Busch RM, Floden D, Lineweaver TT et al. Effect of apolipoprotein ε4 allele on hippocampal and brain volume in intractable temporal lobe epilepsy. Epilepsy Behav 2011; 21:88-90.

Bush AI. The metallobiology of Alzheimer’s disease. Trends Neurosci 2003; 26:207-14.

Busi F, Cresteil T. CYP3A5 mRNA degradation by nonsense-mediated mRNA decay. Mol Pharmacol 2005; 68:808-15.

Businaro R, Fabrizi C, Fumagalli L, Lauro GM. Role of alpha-2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental effect? J Neurochem 2001; 78:406-12.

Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995; 353:116-21.

Busse KH, Penzak SR. Darunavir: a second-generation protease inhibitor. Am J Health Syst Pharm 2007; 64:1593-602.

Buster EH, van Vuuren HJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur J Gastroenterol Hepatol 2008; 1:68-72.

Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24:1732-47.

But WM, Lo IF, Shek CC, Tse WY, Lam ST. Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency. Hong Kong Med J 2010; 16:59-62.

Buters JT, Korzekwa KR, Kunze KL, Omata Y, Hardwick JP, Gonzalez FJ. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 1994; 22:688-92.

Buters JTM, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics 1996; 6:291-6.

Butkiewicz D, Krześniak M, Vaitiekunaite R et al. A functional analysis of G23A polymorphism and the alternative splicing in the expression of the XPA gene. Cell Mol Biol Lett 2010; 15:611-29.

Butler AM, Murray M. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. J Pharmacol Exp Ther 1997; 280:966-73.

Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450(PA) (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Nat Acad Sci USA 1989; 86:7696-700.

Butovsky O, Koronyo-Hamaoui M, Kunis G et al. Glatiramer acetate fights against Alzheimer’s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 2006; 103:11784-9.

Buxbaum JN, Reixach N. Transthyretin: the servant of many masters. Cell Mol Life Sci 2009; 66:3095-101.

Buyske S, Williams TA, Mars AE et al. Analysis of case-parent trios at a locus with a deletion allele: association of GSTM1 with autism. BMC Genet 2006; 7:8.

Buzdar AU, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother 2006; 40:1572-83.

Buzi F, Mella P, Pilotta A et al. Growth hormone receptor polymorphisms. Endocr Dev 2007; 11:28-35.

Buzzetti R, Petrone A, Ribaudo MC et al. The common PPAR-gamma-2 pro12-to-ala variant is associated with greater insulin sensitivity. Europ J Hum Genet 2004; 12:1050-4.

Bylund J, Kunz T, Valmsen K, Oliw EH. Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J Pharmacol Exp Ther 1998; 284:51-60.

Bynoté KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun 2008; 9:137-52.

Byrd JC, Lin TS, Dalton JT et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399-404.

Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28:375-9.

Byrum RS, Goulet JL, Snouwaert JN, Griffiths RJ, Koller BH. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 1999; 163:6810-9.

Byun E, Caillier SJ, Montalban X et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65:337-44.